UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 11, 2019


[F20190315FORM8K1.JPG]


PARALLAX HEALTH SCIENCES, INC.

(Exact name of Company as specified in its charter)

 

Nevada

000-52534

46-4733512

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)


Identification Number)


1327 Ocean Avenue, Suite B

Santa Monica, CA 90401

(Address of principal executive offices)


310-899-4442

(Registrant s Telephone Number)



Copy of all Communications to :

Peter V. Hogan

Buchalter

1000 Wilshire Boulevard, Suite 1500

Los Angeles, CA 90017

(213) 891-0700



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:



¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






As used in this current report and unless otherwise indicated, the terms "we", "us", "our", Company , and Parallax mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.


ITEM 1.01

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT


The disclosures set forth in Item 2.03 are incorporated by into this Item 1.01 by reference.


ITEM 2.03

CREATION  OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT


On February 27, 2019, Parallax Health Sciences, Inc., a Nevada corporation (the Company ), issued a 12% convertible promissory note (the Note ) in the aggregate principal sum of $111,000, pursuant to that certain Securities Purchase Agreement (the Securities Purchase Agreement).  The Note matures November 27, 2019 ( Maturity Date ), and contains a repayment provision for the holder of the Note the right, at its option, to convert the principal sum and any accrued interest, in whole or part, into shares of the Company s common stock at any time on or before the Maturity Date at a conversion rate of  the lower of (i) $0.12 per share; or (ii) 70% of the second lowest sale price during the twenty (20 consecutive trading days on which at least 100 shares of common stock were traded immediately preceding the conversion date.  The proceeds from the Note were received on March 11, 2019, the closing date.


As part of the Securities Purchase Agreement, the noteholder was issued Warrants to purchase 300,000 shares of the Company s common stock at an exercise price of $0.15 per share for a period of five (5) years.


A form of the Note, the Securities Purchase Agreement and the Warrant is attached to this Current Report as exhibits 4.1 , 10.1 , and 10. 2 , respectively, and incorporated herein by reference. The disclosure set forth in this Section 2.03 is intended to be a summary only and is qualified in its entirety by reference to the exhibits.


ITEM 3.02

UNREGISTERED SALES OF EQUITY SECURITIES


The disclosures set forth in Item 2.03 are incorporated by into this Item 3.02 by reference. The issuance of the Notes and Warrants were made in reliance on exemption from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended, on the basis that the Registrant had a pre-existing relationship with the investor and there was no public offering.


ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS


(d) Exhibits


Exhibit

Number

Description of Exhibit

Filing Reference

4.1

12% Convertible P romissory Note dated F ebruary 27 , 2019

Filed herewith

10.1

Form of S ecurities Purchase Agreement dated February 27, 2019

Filed herewith

10.2

Form of Warrant dated February 27, 2019

Filed herewith






SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




 

PARALLAX HEALTH SCIENCES, INC.







 

 



 

 



Dated: March 15, 2019

/s/ Calli R. Bucci



 

Calli R. Bucci



 

Chief Financial Officer










NEITHER   THE   ISSUANCE   AND   SALE   OF   THE   SECURITIES   REPRESENTED   BY   THIS

CERTIFICATE    NOR    THE    SECURITIES    INTO    WHICH    THESE    SECURITIES    ARE

CONVERTIBLE   HAVE   BEEN   REGISTERED   UNDER   THE   SECURITIES   ACT   OF   1933,

AS AMENDED, OR   APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY

NOT  BE  OFFERED  FOR  SALE,  SOLD,  TRANSFERRED  OR  ASSIGNED  (I)  IN  THE

ABSENCE    OF     (A)    AN    EFFECTIVE    REGISTRATION    STATEMENT    FOR    THE

SECURITIES  UNDER  THE  SECURITIES  ACT  OF  1933,  AS  AMENDED,  OR  (B)  AN

OPINION     OF     COUNSEL     (WHICH     COUNSEL     SHALL     BE     SELECTED     BY     THE

HOLDER),   IN   A   GENERALLY   ACCEPTABLE   FORM,   THAT   REGISTRATION   IS   NOT

REQUIRED   UNDER   SAID   ACT   OR   (II)   UNLESS   SOLD   PURSUANT   TO   RULE   144   OR

RULE   144A   UNDER   SAID   ACT.   NOTWITHSTANDING   THE   FOREGOING,   THE

SECURITIES  MAY   BE  PLEDGED   IN   CONNECTION   WITH  A   BONA   FIDE  MARGIN

ACCOUNT   OR   OTHER   LOAN   OR   FINANCING   ARRANGEMENT   SECURED   BY   THE

SECURITIES.

Principal Amount: $111,000.00

Issue Date: February 27, 2019

12% CONVERTIBLE NOTE

FOR   VALUE   RECEIVED , PARALLAX   HEALTH   SCIENCES,   INC.,   a   Nevada

corporation   ( Borrower   or    Company ),   hereby   promises   to   pay   to   the   order   of   EMA

FINANCIAL,   LLC,   a   Delaware   limited   liability   company,   or   its   registered   assigns   (the   Holder ),

on   November   27,   2019,   (subject   to   extension   as   set   forth   below,   the   Maturity   Date ),   the   sum   of

$111,000.00   as   set   forth   herein,   together   with   interest   on   the   unpaid   principal   balance   hereof   at   the

rate   of   twelve   percent   (12%)    per   annum   (the   Interest   Rate )   from   the   date   of   issuance   hereof   until

this   Note   plus   any   and   all   amounts   due   hereunder   are   paid   in   full,   and   any   additional   amounts   set

forth   herein,   including without   limitation   any Additional   Principal   (as   defined   herein).   Interest   shall

be   computed   on   the   basis   of   a   365-day   year   and   the   actual   number   of   days   elapsed.   Any   amount   of

principal or interest on this Note which is not paid when due shall bear interest at the rate of twenty-

four   (24%)   per   annum   from   the   due   date   thereof   until   the   same   is   paid   ( Default   Interest ).   All

payments  due  hereunder  shall  be  made  in  lawful  money   of  the  United  States  of  America.  All

payments   shall   be   made   at   such   address   as   the   Holder   shall   hereafter   give   to   the   Borrower   by

written    notice    made    in    accordance    with    the    provisions    of    this    Note.    Whenever    any    amount

expressed   to   be   due   by   the   terms   of   this   Note   is   due   on   any   day   which   is   not   a   business   day,   the

same shall instead be due on the next succeeding day which is a business day and, in the case of any

interest   payment   date   which   is   not   the   date   on   which   this   Note   is   paid   in   full,   the   extension   of   the

due   date   thereof   shall   not   be   taken   into   account   for   purposes   of   determining   the   amount   of   interest

due   on   such   date.   As   used   in   this   Note,   the   term   business   day   shall   mean   any   day   other   than   a

Saturday,   Sunday   or   a   day   on   which   commercial   banks   in   the   city   of   New   York,   New   York   are

authorized  or   required   by   law   or   executive   order   to   remain   closed.   Each   capitalized   term  used

herein,   and   not   otherwise   defined,   shall   have   the   meaning   ascribed   thereto   in   that   certain   Securities

Purchase   Agreement   entered   into   by   and   between   the   Company   and   Holder   dated   on   or   about   the

date   hereof,   pursuant   to   which   this   Note   was   originally   issued   (the   Purchase   Agreement ).   The

Holder   may,   by   written   notice   to   the   Borrower   at   least   five   (5)   days   before   the   Maturity   Date   (as

may   have   been   previously   extended),   extend   the   Maturity   Date   to   up   to   one   (1)   year   following   the

date of the original Maturity Date hereunder.

1

Convertible Note PRLX, T1, 2019-02-27



This   Note   is   free   from   all   taxes,   liens,   claims   and   encumbrances   with   respect   to   the   issue

thereof   and   shall   not   be   subject   to   preemptive   rights   or   other   similar   rights   of   shareholders   of   the

Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

ARTICLE   I. CONVERSION RIGHTS

1.1.

Conversion   Right.   The   Holder   shall   have   the   right,   in   its   sole   and   absolute

discretion,   at   any   time   from   time   to   time,   to   convert   all   or   any   part   of   the   outstanding   amount   due

under this Note (such outstanding amount includes but is not limited to the principal, interest and/or

Default   Interest   accrued,   plus   any   and   all   other   amounts   owed   pursuant   to   the   terms   of   this   Note)

into   fully   paid   and   non-assessable   shares   of   Common   Stock,   as   such   Common   Stock   exists   on   the

Issue   Date,  or  any   shares  of  capital  stock   or   other   securities  of   the  Borrower   into   which  such

Common   Stock   shall   hereafter   be   changed   or   reclassified   at   the   conversion   price   (the   Conversion

Price )   determined   as   provided   herein   (a   Conversion ); provided, however,   that   in   no   event   shall

the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon

conversion   of   which   the   sum   of   (1)   the   number   of   shares   of   Common   Stock   beneficially   owned   by

the Holder and its affiliates (other than shares of   Common Stock which may be deemed beneficially

owned  through  the  ownership  of  the  unconverted  portion  of  the  Notes  or  the  unexercised  or

unconverted   portion   of   any   other   security   of   the   Borrower   subject   to   a   limitation   on   conversion   or

exercise   analogous   to   the   limitations   contained   herein)   and   (2)   the   number   of   shares   of   Common

Stock    issuable    upon    the    conversion    of    the    portion    of    this    Note    with    respect    to    which    the

determination of this proviso is being made, would result in beneficial ownership by the Holder and

its   affiliates   of   more   than   4.9%   of   the   outstanding   shares   of   Common   Stock.   For   purposes   of   the

proviso    to    the    immediately    preceding    sentence,    beneficial    ownership    shall    be    determined    in

accordance   with   Section   13(d)   of   the   Securities   Exchange   Act   of   1934,   as   amended   (the   Exchange

Act ),  and  Regulation  13D-G  thereunder,  except  as  otherwise  provided  in  clause  (1)  of  such

proviso, provided, further, however, that the limitations on conversion may be waived by the Holder

upon,   at   the   election   of   the   Holder,   not   less   than   61   days   prior   notice   to   the   Borrower,   and   the

provisions   of   the   conversion   limitation   shall   continue   to   apply   until   such   61st   day   (or   such   later

date,   as   determined   by   the   Holder,   as   may   be   specified   in   such   notice   of   waiver).   The   number   of

shares   of   Common   Stock   to   be   issued   upon   each   Conversion   of   this   Note   ( Conversion   Shares )

shall  be  determined  by  dividing  the  Conversion  Amount  (as  defined  below)  by  the  applicable

Conversion  Price  then  in  effect  on  the  date  specified  in  the  notice  of  conversion,  in  the  form

attached   hereto   as   Exhibit   A   (the   Notice   of   Conversion ),   delivered   to   the   Borrower   by the   Holder

in   accordance   with   Section   1.4   below;   provided   that   the   Notice   of   Conversion   is   submitted   by

facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the

Borrower   before   11:59   p.m.,   New   York,   New   York   time   on   such   conversion   date   (the   Conversion

Date ).   The   term   Conversion   Amount   means,   with   respect   to   any   Conversion   of   this   Note,   the

sum   of   (1)   the   principal   amount   of   this   Note   to   be   converted   in   such   Conversion, plus (2)   accrued

and   unpaid   interest,   if   any,   to   be   converted   in   such   Conversion   at   the   interest   rates   provided   in   this

Note to the Conversion Date, plus ( 3) at the Holder s option, Default Interest, if any, on the amounts

referred   to   in   the   immediately preceding clauses   (1)   and/or   (2), plus ( 4) any Additional   Principal   for

such   Conversion,   plus ( 5)   at   the   Holder s   option,   any   amounts   owed   to   the   Holder   pursuant   to

Sections 1.2(c) and 1.4(g) hereof.

2

Convertible Note PRLX, T1, 2019-02-27



1.2.

Conversion Price .

a)

Calculation   of   Conversion   Price . The   conversion   price   hereunder   (the

Conversion Price ) shall equal the lower of: (i) $0.12, and (ii) 70% of either the second lowest sale

price   for   the   Common   Stock   on   the   Principal   Market   during   the   twenty   (20)   consecutive   Trading

Days  on  which  at  least  100  shares  of  Common  Stock  were  traded  including  and  immediately

preceding   the   Conversion   Date.   If   an   Event   of   Default   under   Section   3.9   of   the   Note   has   occurred,

Holder, in its sole discretion, may elect to use a Conversion Price which shall equal the lower of: (i)

the    closing    sale    price    of    the    Common    Stock    on    the    Principal    Market    on    the    Trading    Day

immediately   preceding   the   Closing   Date;   (ii)   70%   of   either   the   lowest   sale   price   or   the   closing   bid

price, whichever is lower for the Common Stock on the Principal Market during any Trading Day in

which the Event of Default has not been cured. If such Common Stock is not traded on the OTCBB,

OTCQB,   NASDAQ   or   NYSE,   then   such   sale   price   shall   be   the   sale   price   of   such   security   on   the

principal   securities   exchange   or   trading   market   where   such   security   is   listed   or   traded   or,   if   no   sale

price   of   such   security   is   available   in   any   of   the   foregoing   manners,   the   average   of   the   closing   bid

prices   of   any   market   makers   for   such   security   that   are   listed   in   the   pink   sheets   by   the   National

Quotation   Bureau,   Inc.   If   such   sale   price   cannot   be   calculated   for   such   security   on   such   date   in   the

manner   provided   above,   such   price   shall   be   the   fair   market   value   as   mutually   determined   by   the

Borrower   and   the   Holder.   If   the   Borrower s   Common   stock   is   chilled   for   deposit   at   DTC,   becomes

chilled   at   any   point   while   this   Note   remains   outstanding   or   deposit   or   other   additional   fees   are

payable due to a Yield Sign, Stop Sign or other trading restrictions, or if the closing sale price at any

time   falls   below   $0.0275   (as   appropriately   and   equitably   adjusted   for   stock   splits,   stock   dividends,

stock   contributions   and   similar   events),   then   an   additional   15%   discount   will   be   attributed   to   the

Conversion  Price  for  any  and  all  Conversions  submitted  thereafter  Additionally,  the  Borrower

acknowledges   that   it   will   take   all   reasonable   steps   necessary   or   appropriate,   including   providing   a

board   of   directors   resolution   authorizing   the   issuance   of   common   stock   to   Holder.   So   long   as   the

requested   sale   may   be   made   pursuant   to   Rule   144,   the   Company   agrees   to   accept   an   opinion   of

counsel   to   the   Holder   confirming   the   rights   of   the   Holder   to   sell   shares   of   Common   Stock   issuable

or   issued   to   Holder   on   conversion   of   this   Note   pursuant   to   Rule   144   as   promulgated   by   the   SEC

( Rule   144 )   (or   if   applicable   pursuant   to   Rule   4(a)(1)   ( 4(a)(1) ),   as   promulgated   by   the   SEC),   or

at the Holder s option, Company shall immediately and without delay provide an opinion of counsel

to   the   Holder   confirming   the   rights   of   the   Holder   to   sell   shares   of   Common   Stock   pursuant   to   Rule

144,   or   Rule   4(a)(1),   if   applicable,   as   such   Rule   144   may   be   in   effect   from   time   to   time,   which

opinion   will   be   issued   at   the   Company s   expense   and   the   conversion   dollar   amount   will   be   reduced

by $500.00 to cover the cost of such legal opinion.   Trading Day shall mean any day on which the

Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or

other  securities  market  on  which  the  Common  Stock  is  then  being   traded.  Additionally,  if  the

Company   ceases   to   be   a   reporting   company   pursuant   to   the   1934   Act   or   if   the   Note   cannot   be

converted into free trading shares after 181 days from the issuance date, an   additional 15% discount

will be attributed to the Conversion Price for any and all Conversions submitted thereafter.

b)

If   at   any   time   the   Conversion   Price   as   determined   hereunder   for   any

Conversion   would   be   less   than   the   par   value   of   the   Common   Stock,   then   the   Conversion   Price

hereunder   shall   equal   such   par   value   for   such   Conversion   and   the   Conversion   Amount   for   such

Conversion   shall   be   increased   to   include   Additional   Principal,   where   Additional   Principal   means

such   additional   amount   to   be   added   to   the   Conversion   Amount   to   the   extent   necessary   to   cause   the

number    of    Conversion    Shares    issuable    upon    such    Conversion    to    equal    the    same    number    of

3

Convertible Note PRLX, T1, 2019-02-27



Conversion   Shares   as   would   have   been   issued   had   the   Conversion   Price   not   been   subject   to   the

minimum price set forth in this Section 1.2(b).

c)

Without    in    any    way    limiting    the    Holder s    right    to    pursue    other

remedies,   including   actual   damages   and/or   equitable   relief,   the   parties   agree   that   if   delivery   of   the

free   trading   shares   of   Common   Stock   issuable   upon   conversion   of   this   Note   is   not   delivered   by   the

Deadline   (as   defined   below)   the   Borrower   shall   pay to   the   Holder   $250.00   per   day in   cash,   for   each

day beyond   the   Deadline   that   the   Borrower   fails   to   deliver   such   Common   Stock.   Such   cash   amount

shall be paid to Holder by the fifth day of the month following the month in which it has accrued or,

at   the   option   of   the   Holder,   shall   be   added   to   the   principal   amount   of   this   Note,   in   which   event

interest   shall   accrue   thereon   in   accordance   with   the   terms   of   this   Note   and   such   additional   principal

amount   shall   be   convertible   into   Common   Stock   in   accordance   with   the   terms   of   this   Note.   The

Borrower   agrees   that   the   right   to   convert   this   Note   is   a   valuable   right   to   the   Holder.   The   damages

resulting   from   a   failure,   attempt   to   frustrate,   or   interference   with   such   conversion   right   are   difficult

if   not   impossible   to   quantify.   Accordingly,   the   parties   acknowledge   that   the   liquidated   damages

provision contained in this Section are justified.

1.3.

Authorized  Shares.  The  Borrower  covenants  that  the  Borrower  will  at  all

times   while   this   Note   is   outstanding   reserve   from   its   authorized   and   unissued   Common   Stock   a

sufficient   number   of   shares,   free   from   preemptive   rights,   to   provide   for   the   issuance   of   Common

Stock   upon   the   full   conversion   or   adjustment   of   this   Note.   The   Borrower   is   required   at   all   times   to

have authorized and reserved seven (7) times the number of shares that is actually issuable upon full

conversion   or   adjustment   of   this   Note   (based   on   the   Conversion   Price   of   the   Notes   in   effect   from

time   to   time)(the   Reserved   Amount ).    Initially,   the   Company   will   instruct   the   Transfer   Agent   to

reserve   ten   million   one   hundred   thousand   (10,100,000)   shares   of   common   stock   in   the   name   of   the

Holder   for   issuance   upon   conversion   hereof.     The   Borrower   represents   that   upon   issuance,   such

shares   will   be   duly   and   validly   issued,   fully   paid   and   non-assessable.   In   addition,   if   the   Borrower

shall  issue  any   securities  or  make  any   change  to  its  capital  structure  which  would  change  the

number   of   shares   of   Common   Stock   into   which   this   Note   shall   be   convertible   at   the   then   current

Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there

shall  be  a  sufficient  number  of  shares  of  Common  Stock  authorized  and  reserved,  free  from

preemptive  rights,  for  conversion  of  this  Note  in  full.  So  long   as  this  Note  is  outstanding  the

Borrower   shall   instruct   the   Transfer   Agent   that   upon   Holder s   request   it   shall   furnish   to   the   Holder

the   then   current   number   of   common   shares   issued   and   outstanding,   the   then   current   number   of

common   shares   authorized,   the   then   current   number   of   unrestricted   shares,   and   the   then   current

number   of   shares   reserved   for   third   parties.   The   Borrower   (i)   acknowledges   that   it   has   irrevocably

instructed   its   transfer   agent   to   issue   certificates   for   the   Common   Stock   issuable   upon   conversion   of

this   Note,   and   (ii)   agrees   that   its   issuance   of   this   Note   shall   constitute   full   authority   to   its   officers

and   agents   who   are   charged   with   the   duty   of   executing   stock   certificates   to   execute   and   issue   the

necessary   certificates   for   shares   of   Common   Stock   in   accordance   with   the   terms   and   conditions   of

this Note.

If,   at   any   time   the   Borrower   does   not   maintain   the   Reserved   Amount   it   will

be considered an Event of Default under Section 3.2 of the Note.

1.4.

Method of Conversion.

4

Convertible Note PRLX, T1, 2019-02-27



a)

Mechanics   of   Conversion.   Subject   to   Section   1.1,   this   Note   may   be

converted   by   the   Holder   in   whole   or   in   part   at   any   time   and   from   time   to   time   after   the   Issue   Date,

by   submitting   to   the   Borrower   a   Notice   of   Conversion   (by   facsimile,   e-mail   or   other   reasonable

means   of   communication   dispatched   on   the   Conversion   Date   prior   to   11:59   p.m.,   New   York,   New

York time).

b)

Book   Entry    upon   Conversion.   Notwithstanding   anything   to   the

contrary   set   forth   herein,   upon   conversion   of   this   Note   in   accordance   with   the   terms   hereof,   the

Holder   shall   not   be   required   to   physically   surrender   this   Note   to   the   Borrower   unless   the   entire

unpaid   balance   of   this   Note   is   so   converted.   The   Holder   and   the   Borrower   shall   maintain   records

showing the principal amount so converted and the dates of such conversions or shall use such other

method,  reasonably   satisfactory   to  the  Holder  and  the  Borrower,  so  as  not  to  require  physical

surrender   of   this   Note   upon   each   such   conversion.   In   the   event   of   any   dispute   or   discrepancy,   such

records  of  the  Borrower  shall, prima facie, be  controlling  and  determinative  in  the  absence  of

manifest   error.   Notwithstanding   the   foregoing,   if   any portion   of   this   Note   is   converted   as   aforesaid,

the   Holder   may   not   transfer   this   Note   unless   the   Holder   first   physically   surrenders   this   Note   to   the

Borrower,   whereupon   the   Borrower   will   forthwith   issue   and   deliver   upon   the   order   of   the   Holder   a

new   Note   of   like   tenor,   registered   as   the   Holder   (upon   payment   by   the   Holder   of   any   applicable

transfer   taxes)   may request,   representing in   the   aggregate   the   remaining unpaid   principal   amount   of

this Note. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by

reason  of   the   provisions  of   this  paragraph,   following   conversion   of   a   portion   of   this  Note,  the

unpaid and unconverted principal amount of this Note represented by this Note may be less than the

amount stated on the face hereof.

c)

Payment   of   Taxes.   The   Borrower   shall   not   be   required   to   pay   any tax

which   may   be   payable   in   respect   of   any   transfer   involved   in   the   issue   and   delivery   of   shares   of

Common   Stock   or   other   securities   or   property   on   conversion   of   this   Note   in   a   name   other   than   that

of the Holder (or in street name), and the Borrower shall not be required to issue or deliver any such

shares or other securities or property unless and until the person or persons (other than the Holder or

the   custodian   in   whose   street   name   such   shares   are   to   be   held   for   the   Holder s   account)   requesting

the   issuance   thereof   shall   have   paid   to   the   Borrower   the   amount   of   any   such   tax   or   shall   have

established to the satisfaction of the Borrower that such tax has been paid.

d)

Delivery   of   Common   Stock   upon   Conversion. Upon   receipt  by   the

Borrower   from   the   Holder   of   a   facsimile   transmission   or   e-mail   (or   other   reasonable   means   of

communication)   of   a   Notice   of   Conversion   meeting   the   requirements   for   conversion   as   provided   in

this   Section   1.4,   the   Borrower   shall   issue   and   deliver   or   cause   to   be   issued   and   delivered   to   or   upon

the   order   of   the   Holder   certificates   for   the   Common   Stock   issuable   upon   such   conversion   within

three   (3)   business   days   after   such   receipt   or   such   an   event   (the   Deadline )   (and,   solely   in   the   case

of   conversion   of   the   entire   unpaid   principal   amount   hereof,   surrender   of   this   Note)   in   accordance

with the terms hereof and the Purchase Agreement.

e)

Obligation   of   Borrower   to   Deliver   Common   Stock.   Upon   receipt   by

the   Borrower   of   a   duly and   properly executed   Notice   of   Conversion,   the   Holder   shall   be   deemed   to

be  the  holder  of  record  of  the  Common  Stock  issuable  upon  such  conversion,  the  outstanding

principal   amount   and   the   amount   of   accrued   and   unpaid   interest   on   this   Note   shall   be   reduced   to

reflect   such   conversion   or   adjustment,   and,   unless   the   Borrower   defaults   on   its   obligations   under

this   Article   I,   all   rights   with   respect   to   the   portion   of   this   Note   being   so   converted   shall   forthwith

5

Convertible Note PRLX, T1, 2019-02-27



terminate   except   the   right   to   receive   the   Common   Stock   or   other   securities,   cash   or   other   assets,   as

herein   provided,   on   such   conversion.   If   the   Holder   shall   have   given   a   Notice   of   Conversion   as

provided   herein,   the   Borrower s   obligation   to   issue   and   deliver   the   certificates   for   Common   Stock

shall   be   absolute   and   unconditional,   irrespective   of   the   absence   of   any   action   by   the   Holder   to

enforce   the   same,   any   waiver   or   consent   with   respect   to   any   provision   thereof,   the   recovery   of   any

judgment    against    any  person    or    any  action    to    enforce    the    same,    any  failure    or    delay  in    the

enforcement    of    any  other    obligation    of    the    Borrower    to    the    holder    of    record,    or    any  setoff,

counterclaim,   recoupment,   limitation   or   termination,   or   any   breach   or   alleged   breach   by   the   Holder

of    any    obligation    to    the    Borrower,    and    irrespective    of    any    other    circumstance    which    might

otherwise   limit   such   obligation   of   the   Borrower   to   the   Holder   in   connection   with   such   conversion.

The Conversion   Date specified in the   Notice   of Conversion shall be   the Conversion Date so long as

the   Notice   of   Conversion   is   received   by   the   Borrower   before   11:59   p.m.,   New   York,   New   York

time, on such date.

f)

Delivery    of    Common    Stock    by    Electronic    Transfer .    In    lieu    of

delivering   physical   certificates   representing   the   Common   Stock   issuable   upon   conversion,   provided

the   Borrower   is   participating in   the   Depository Trust   Company ( DTC )   Fast   Automated   Securities

Transfer   ( FAST )   program,   upon   request   of   the   Holder   and   its   compliance   with   the   provisions

contained   in   Section   1.1   and   in   this   Section   1.4,   the   Borrower   shall   use   its   best   efforts   to   cause   its

transfer   agent   to   electronically   transmit   the   Common   Stock   issuable   upon   conversion   to   the   Holder

by crediting the account   of Holder s Prime Broker with DTC through its Deposit Withdrawal Agent

Commission   ( DWAC )   system.    In   the   event   that   the   shares   of   the   Borrower s   Common   Stock   are

not   deliverable   via   DWAC   following   the   conversion   of   any   amount   hereunder,   an   additional   5%

discount will be attributed to the Conversion Price.

g)

Failure   to   Deliver   Common   Stock   Prior   to   Deadline . Without   in   any

way limiting the Holder s right to pursue other remedies, including actual   damages and/or   equitable

relief,    the    parties    agree    that    if    delivery    of    the    Common    Stock    issuable    upon    conversion    or

adjustment   of   this   Note   is   not   delivered   by   the   Deadline,   the   Borrower   shall   pay   to   the   Holder

$250.00   per   day   in   cash,   for   each   day   beyond   the   Deadline   that   the   Borrower   fails   to   deliver   such

Common   Stock   to   the   Holder.   Such   cash   amount   shall   be   paid   to   Holder   by   the   fifth   day   of   the

month following the month in which it has accrued or, at the option of the Holder, shall be added to

the   principal   amount   of   this   Note,   in   which   event   interest   shall   accrue   thereon   in   accordance   with

the terms of this Note and such additional principal amount shall be convertible into Common Stock

in   accordance   with   the   terms   of   this   Note.   The   Borrower   agrees   that   the   right   to   convert   and/or

receive shares in the event of an adjustment is a valuable right to the Holder. The damages resulting

from   a   failure,   attempt   to   frustrate,   or   interference   with   such   conversion   or   adjustment   right   are

difficult  if  not  impossible  to  qualify.  Accordingly,  the  parties  acknowledge  that  the  liquidated

damages provision contained in this Section 1.4(g) are justified.

h)

The  Borrower  acknowledges  that  it  will  take  all  reasonable  steps

necessary or   appropriate,   including   accepting an   opinion   of   counsel   to   Holder   confirming   the   rights

of Holder to sell shares of Common Stock issued to Holder on conversion or adjustment of the Note

pursuant   to   Rule   144   as   promulgated   by the   SEC   ( Rule   144"),   as   such   Rule   may be   in   effect   from

time   to   time.   So   long   as   the   requested   sale   may   be   made   pursuant   to   Rule   144   the   Borrower   agrees

to  accept  an  opinion   of  counsel  to   the   Holder  which   opinion   will  be   issued   at  the   Borrower s

expense.

6

Convertible Note PRLX, T1, 2019-02-27



i)

Charges   and   Expenses.   Issuance   of   Common   Stock   to   Holder,   or   any

of   its   assignees,   upon   the   conversion   of   this   Note   shall   be   made   without   charge   to   the   Holder   for

any issuance fee, transfer tax, legal opinion and related charges, postage/mailing charge or any other

expense with respect to the issuance of such Common Stock. Company shall pay all Transfer Agent

fees   incurred   from   the   reservation   and   issuance   of   the   Common Stock to   Holder,   as   well   as   any and

all    other    fees    and    charges    required    by  the    Transfer    Agent    as    a    condition    to    effectuate    such

issuance. That   notwithstanding,   the   Holder   may   in   the   interest   of   securing   issuance   and/or   delivery

of   Common   Stock   before   the   Deadline,   at   any   time   from   time   to   time,   in   its   sole   discretion   elect   to

pay any such fees or   charges upfront, and Company agrees that any such fees or charges as noted in

this   Section   that   are   paid   by   the   Holder   (whether   from   the   Company s   delays,   outright   refusal   to

pay,   Holder s   interest   in   securing   issuance   and/or   delivery   of   Common   Stock   before   the

Deadline, or     otherwise), will     be     at     Company s     expense, and     the     conversion     amount     will

automatically   be   reduced   by   that   dollar   amount   to   cover   the   cost   of   the   fees   or   charges   as   noted   in

this Section.

1.5.

Restricted Securities. The shares of Common Stock issuable upon   conversion

or   adjustment   of   this   Note   may not   be   sold   or   transferred   unless   (i)   such   shares   are   sold   pursuant   to

an   effective   registration   statement   under   the   Act   or   (ii)   the   Borrower   or   its   transfer   agent   shall   have

been   furnished   with   an   opinion   of   counsel   (which   opinion   shall   be   in   form,   substance   and   scope

customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold

or   transferred   may   be   sold   or   transferred   pursuant   to   an   exemption   from   such   registration   or   (iii)

such   shares   are   sold   or   transferred   pursuant   to   Rule   144   under   the   Act   (or   a   successor   rule)   ( Rule

144 )   or   (iv)   such   shares   are   transferred   to   an   affiliate   (as   defined   in   Rule   144)   of   the   Borrower

who agrees to sell or otherwise transfer the shares   only in accordance with   this Section 1.5 and who

is   an   Accredited   Investor   (as   defined   in   the   Purchase   Agreement).     Any   legend   set   forth   on   any

stock   certificate   evidencing   any   Conversion   Shares   shall   be   removed   and   the   Borrower   shall   issue

to the Holder a new certificate therefore free of any transfer legend if (i) the Borrower or its transfer

agent    shall    have    received    an    opinion    of    counsel      form,  substance  and  scope  customary  for

opinions   of   counsel   in  comparable   transactions,   to   the   effect   that   a  public   sale   or  transfer   of   such

Common   Stock   may be   made   without   registration   under   the   Act,   which   opinion   shall   be reasonably

acceptable  to  the  Company,  or  (ii)  in  the  case  of  the  Common  Stock  issued  or  issuable  upon

conversion  of  this  Note,  such  security  is  registered  for  sale  by  the  Holder  under  an  effective

registration   statement   filed   under   the   Act   or   otherwise   may   be   sold   pursuant   to   Rule   144   without

any   restriction   as   to   the   number   of   securities   as   of   a   particular   date   that   can   then   be   immediately

sold.

1.6.

Effect of Certain Events.

a)

Effect   of   Merger,   Consolidation,   Etc .   At   the   option   of   the   Holder,   the

sale,    conveyance    or    disposition    of    all    or    substantially  all    of    the    assets    of    the    Borrower,    the

effectuation   by   the   Borrower   of   a   transaction   or   series   of   related   transactions   in   which   more   than

50%   of   the   voting   power   of   the   Borrower   is   disposed   of,   or   the   consolidation,   merger   or   other

business   combination   of   the   Borrower   with   or   into   any   other   Person   (as   defined   below)   or   Persons

when   the   Borrower   is   not   the   survivor   shall   either:   (i)   be   deemed   to   be   an   Event   of   Default   (as

defined   in   Article   III)   pursuant   to   which   the   Borrower   shall   be   required   to   pay   to   the   Holder   upon

the consummation of   and   as a   condition to such   transaction an   amount equal to the Default Amount

(as   defined   in   Article   III)   or   (ii)   be   treated   pursuant   to   Section   1.6(b)   hereof.   Person   shall   mean

7

Convertible Note PRLX, T1, 2019-02-27



any   individual,   corporation,   limited   liability   company,   partnership,   association,   trust   or   other   entity

or organization.

b)

Adjustment   Due   to   Merger,   Consolidation,   Etc .   If,   at   any   time   when

this   Note   is   issued   and   outstanding   and   prior   to   conversion   of   all   of   the   Notes,   there   shall   be   any

merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as

a   result   of   which   shares   of   Common   Stock   of   the   Borrower   shall   be   changed   into   the   same   or   a

different   number   of   shares   of   another   class   or   classes   of   stock   or   securities   of   the   Borrower   or

another   entity,   or   in   case   of   any   sale   or   conveyance   of   all   or   substantially   all   of   the   assets   of   the

Borrower   other   than   in   connection   with   a   plan   of   complete   liquidation   of   the   Borrower,   then   the

Holder   of   this   Note   shall   thereafter   have   the   right   to   receive   upon   conversion   of   this   Note,   upon   the

basis and upon the terms and conditions specified herein and in lieu of the   shares of Common Stock

immediately theretofore   issuable   upon   conversion,   such   stock,   securities   or   assets   which   the   Holder

would  have  been  entitled  to  receive  in  such  transaction  had  this  Note  been  converted  in  full

immediately   prior   to   such   transaction   (without   regard   to   any   limitations   on   conversion   set   forth

herein),   and   in   any   such   case   appropriate   provisions   shall   be   made   with   respect   to   the   rights   and

interests  of  the  Holder  of  this  Note  to  the  end  that  the  provisions  hereof  (including,  without

limitation,   provisions   for   adjustment   of   the   Conversion   Price   and   of   the   number   of   shares   issuable

upon   conversion   of   the   Note)   shall   thereafter   be   applicable,   as   nearly   as   may   be   practicable   in

relation   to   any   securities   or   assets   thereafter   deliverable   upon   the   conversion   hereof.   The   Borrower

shall   not   affect   any transaction   described   in   this   Section   1.6(b)   unless   (a)   it   first   gives,   to   the   extent

practicable,   thirty   (30)   days   prior   written   notice   (but   in   any   event   at   least   fifteen   (15)   days   prior

written   notice)   of   the   record   date   of   the   special   meeting of   shareholders   to   approve,   or   if   there   is   no

such   record   date,   the   consummation   of,   such   merger,   consolidation,   exchange   of   shares,

recapitalization,  reorganization  or  other  similar  event  or  sale  of  assets  (during  which  time,  for

clarification,   the   Holder   shall   be   entitled   to   convert   this   Note)   and   (b)   the   resulting   successor   or

acquiring   entity   assumes   by   written   instrument   the   obligations   of   this   Section   1.6(b).   The   above

provisions  shall  similarly  apply  to  successive  consolidations,  mergers,  sales,  transfers  or  share

exchanges.

c)

Adjustment Due to Distribution . If the Borrower shall declare or make

any   distribution   of   its   assets   (or   rights   to   acquire   its   assets)   to   holders   of   Common   Stock   as   a

dividend,   stock   repurchase,   by   way   of   return   of   capital   or   otherwise   (including   any   dividend   or

distribution   to   the   Borrower s   shareholders   in   cash   or   shares   (or   rights   to   acquire   shares)   of   capital

stock   of   a   subsidiary   (i.e.,   a   spin-off))   (a   Distribution ),   then   the   Holder   of   this   Note   shall   be

entitled, upon any conversion of this Note as of or after (in the event of a stock dividend) the date of

record   for   determining   shareholders   entitled   to   such   Distribution,   to   receive   the   amount   of   such

assets   which   would   have   been   payable   to   the   Holder   with   respect   to   the   shares   of   Common   Stock

issuable upon such conversion had such Holder been the holder of such shares of Common Stock on

the record date for the determination of shareholders entitled to such Distribution.    Such assets shall

be held in escrow by the Company pending any such conversion

d)

Purchase  Rights.    If,  at    any  time  when  any  Notes  are  issued    and

outstanding,   the   Borrower   issues   any   convertible   securities   or   rights   to   purchase   stock,   warrants,

securities   or   other   property   (the   Purchase   Rights )   pro   rata   to   the   record   holders   of   any   class   of

Common   Stock,   then   the   Holder   of   this   Note   will   be   entitled   to   acquire,   upon   the   terms   applicable

to   such   Purchase   Rights,   the   aggregate   Purchase   Rights   which   such   Holder   could   have   acquired   if

such Holder had held the number of shares of Common Stock acquirable   upon complete conversion

8

Convertible Note PRLX, T1, 2019-02-27



of   this   Note   (without   regard   to   any limitations   on   conversion   contained   herein)   immediately before

the   date   on   which   a   record   is   taken   for   the   grant,   issuance   or   sale   of   such   Purchase   Rights   or,   if   no

such record is taken, the date as of which the record holders of Common Stock are to be determined

for the grant, issue or sale of such Purchase Rights.

e)

Stock   Dividends   and   Stock   Splits.    If   the   Company,   at   any time   while

this Note is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions

payable   in   shares   of   Common   Stock   on   shares   of   Common   Stock   or   any   securities   convertible   into

or   exercisable   for  Common   Stock;  (B)   subdivides  outstanding   shares  of   Common   Stock  into   a

larger number of shares; (C) combines (including by way of a reverse stock split) outstanding shares

of Common Stock into a smaller number of shares; or (D) issues, in the event of a reclassification of

shares of the Common Stock, any shares of capital stock of the Company, then the Conversion Price

(and   each   sale   or   bid   price   used   in   determining   the   Conversion   Price)   shall   be   subject   to   equitable

adjustments for such events.

f)

Any adjustment   made   pursuant   to   this   Section   shall   become   effective

immediately   after   the   record   date   for   the   determination   of   stockholders   entitled   to   receive   such

dividend   or   distribution   and   shall   become   effective   immediately   after   the   effective   date   in   the   case

of a subdivision, combination or re-classification.

g)

Notice   of   Adjustments .   Upon   the   occurrence   of   each   adjustment   or

readjustment   of   the   Conversion   Price   as   a   result   of   the   events   described   in   this   Section   1.6,   the

Borrower,   at   its   expense,   shall   promptly compute   such   adjustment   or   readjustment   and   prepare   and

furnish   to   the   Holder   a   certificate   setting   forth   such   adjustment   or   readjustment   and   showing   in

detail   the   facts   upon   which   such   adjustment   or   readjustment   is   based.   The   Borrower   shall,   upon   the

written   request   at   any   time   of   the   Holder,   furnish   to   such   Holder   a   like   certificate   setting   forth   (i)

such   adjustment   or   readjustment,   (ii)   the   Conversion   Price   at   the   time   in   effect   and   (iii)   the   number

of shares of Common Stock and the amount, if any, of other securities or property which at the time

would be received upon conversion of the Note.

1.7.

Revocation.   If   any   Conversion   Shares   are   not   received   by   the   Deadline,   the

Holder   may   revoke   the  applicable   Conversion   pursuant   to   which   such   Conversion   Shares  were

issuable.    This   Note   shall   remain   convertible   after   the   Maturity Date   hereof   until   this   Note   is repaid

or converted in full.

1.8.

Prepayment. Notwithstanding anything to the contrary contained in this Note,

subject to the terms of this Section, at any time during the period beginning on the Closing Date and

ending   on   the   date   which   is   six   (6)   months   following   the   Issue   Date   ( Prepayment   Termination

Date ),   Borrower   shall   have   the   right,   exercisable   on   not   less   than   five   (5)   Trading   Days   prior

written   notice   to   the   Holder   of   this   Note,   to   prepay   up   to   the   outstanding   balance   on   this   Note

(principal   and   accrued   interest),   in   full,   in   accordance   with   this   Section.   Any   notice   of   prepayment

hereunder   (an   Optional   Prepayment   Notice )   shall   be   delivered   to   the   Holder   of   the   Note   at   its

registered   addresses   and   shall   state:   (1)   that   the   Borrower   is   exercising   its   right   to   prepay   the   Note,

and   (2)   the   date   of   prepayment   which   shall   be   not   more   than   fifteen   (15)   Trading   Days   from   the

date of the Optional Prepayment Notice; and (3) the amount (in dollars) that the Borrower is paying.

Notwithstanding   Holder s   receipt   of   the   Optional   Prepayment   Notice   the   Holder   may   convert,   or

continue   to   convert   the   Note   in   whole   or   in   part   until   the   Optional   Prepayment   Amount   (as   defined

herein)   is   paid   to   the   Holder.    On   the   date   fixed   for   prepayment   (the   Optional   Prepayment   Date ),

9

Convertible Note PRLX, T1, 2019-02-27



the   Borrower   shall   make   payment   of   the   Optional   Prepayment   Amount   (as   defined   below)   to   or

upon   the   order   of   the   Holder   as   specified   by   the   Holder   in   writing   to   the   Borrower   at   least   one   (1)

business   day   prior   to   the   Optional   Prepayment   Date.    If   the   Borrower   exercises   its   right   to   prepay

the   Note,   the   Borrower   shall   make   payment   to   the   Holder   of   an   amount   in   cash   (the   Optional

Prepayment Amount ) equal to the Prepayment Factor (as defined below), multiplied by the sum of:

(w)   the   then   outstanding   principal   amount   of   this   Note plus ( x)   accrued   and   unpaid   interest   on   the

unpaid   principal   amount   of   this   Note   to   the   Optional   Prepayment   Date plus ( y)   Default   Interest,   if

any,   on   the   amounts   referred   to   in   clauses   (w)   and   (x) plus ( z)   any   amounts   owed   to   the   Holder

pursuant to Sections 1.3 and 1.4(g) hereof.  If the Borrower delivers an Optional Prepayment Notice

and   fails   to   pay   the   Optional   Prepayment   Amount   due   to   the   Holder   of   the   Note   within   two   (2)

business days following the Optional Prepayment Date, the Borrower shall forever forfeit its right to

prepay   the   Note   pursuant   to   this   Section.   After   the   Prepayment   Termination   Date,   the   Borrower

shall   have   no   right   to   prepay   this   Note.   For   purposes   hereof,   the   Prepayment   Factor   shall   equal

the    percentage    set    forth    below    with    respect    to    each    Optional    Prepayment    Date    beside    such

Prepayment Factor:

The Prepayment Factor is:

If the Optional Prepayment Date occurs:

110%

1-90 days after the Issue Date

120%

91-120 days after the Issue Date

140%

121-180 days after the Issue Date

ARTICLE II. CERTAIN COVENANTS

2.1.

Distributions  on  Capital  Stock.  So  long  as  the  Borrower  shall  have  any

obligation   under   this   Note,   the   Borrower   shall   not   without   the   Holder s   written   consent   (a)   pay,

declare   or   set   apart   for   such   payment,   any   dividend   or   other   distribution   (whether   in   cash,   property

or   other   securities)   on   shares   of   capital   stock   other   than   dividends   on   shares   of   Common   Stock

solely in the form of additional shares of Common Stock or (b) directly or   indirectly or through any

subsidiary  make    any  other    payment    or    distribution    in    respect    of    its    capital    stock    except    for

distributions  pursuant  to  any   shareholders  rights  plan  which  is  approved  by   a  majority   of  the

Borrower s disinterested directors.

2.2.

Restriction   on   Stock   Repurchases.   So   long   as   the   Borrower   shall   have   any

obligation   under   this   Note,   the   Borrower   shall   not   without   the   Holder s   written   consent   redeem,

repurchase   or   otherwise   acquire   (whether   for   cash   or   in   exchange   for   property or   other   securities   or

otherwise)   in   any   one   transaction   or   series   of   related   transactions   any   shares   of   capital   stock   of   the

Borrower or any warrants, rights or options to purchase or acquire any such shares.

2.3.

[Intentionally Omitted].

2.4.

Sale   of   Assets.   So   long   as   the   Borrower   shall   have   any   obligation   under   this

Note,   the   Borrower   shall   not,   without   the   Holder s   written   consent,   sell,   lease   or   otherwise   dispose

10

Convertible Note PRLX, T1, 2019-02-27



of   any   significant   portion   of   its   assets   outside   the   ordinary   course   of   business.   Any   consent   to   the

disposition of any assets may be conditioned on a specified use of the proceeds of disposition.

2.5.

Advances  and  Loans.  So  long  as  the  Borrower  shall  have  any   obligation

under   this   Note,   the   Borrower   shall   not,   without   the   Holder s   written   consent,   lend   money,   give

credit  or  make  advances  to  any  person,  firm,  joint  venture  or  corporation,  including,  without

limitation,   officers,   directors,   employees,   subsidiaries   and   affiliates   of   the   Borrower,   except   loans,

credits  or   advances  in   existence   or   committed   on   the   date   hereof  and  which   the   Borrower   has

informed Holder in writing prior to the date hereof.

2.6.

Charter.    So   long as   the   Borrower   shall   have   any obligations   under   this   Note,

the   Borrower   shall   not   amend   its   charter   documents,   including   without   limitation   its   certificate   of

incorporation   and   bylaws,   in   any   manner   that   materially   and   adversely   affects   any   rights   of   the

Holder.

2.7.

Transfer Agent.    The   Borrower   shall not   change   its transfer   agent without the

prior   written   consent   of   the   Holder.     Any   replacement   of   the   transfer   agent   by   the   Borrower,   or

resignation   by   the   transfer   agent   without   a   replacement   transfer   agent   consented   to   by   the   Holder

prior to such replacement taking effect shall constitute an Event of Default hereunder.

2.8.

Section   3(a)(9)   or   3(a)(10)   Transaction.   S o   long   as   this   Note   is   outstanding,

the   Borrower   shall   not   enter   into   any   transaction   or   arrangement   structured   in   accordance   with,

based upon, or related or   pursuant to, in whole or in part, either Section 3(a)(9) of the Securities Act

(a   3(a)(9)   Transaction )   or   Section   3(a)(l0)   of   the   Securities   Act   (a   3(a)(l0)   Transaction ).   In   the

event   that   the   Borrower   does   enter   into,   or   makes   any   issuance   of   Common   Stock   related   to   a

3(a)(9)   Transaction   or   a   3(a)(10)   Transaction   while   this   Note   is   outstanding,   a   liquidated   damages

charge   of   25%   of   the   outstanding principal   balance   of   this   Note,   but   not   less   than   Fifteen   Thousand

Dollars $15,000, will be assessed and will become immediately due and payable to the Holder at its

election in the form of cash payment or addition to the balance of this Note.

ARTICLE III. EVENTS OF DEFAULT

Any one or more of   the following events which shall occur   and/or be   continuing shall

constitute an event of default (each, an Event of Default ):

3.1.

Failure   to   Pay   Principal   or   Interest. The   Borrower   fails   to   pay   the   principal

hereof    or    interest    thereon    when    due    on    this  Note,    whether    at    maturity,    upon    acceleration    or

otherwise.

3.2.

Conversion   and   the   Shares. The   Borrower   fails   to   issue   shares   of   Common

Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so

at   any time   following   the   execution   hereof   or)   upon   exercise   by the   Holder   of   the   conversion   rights

of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to

transfer   (issue)   (electronically   or   in   certificated   form)   any   certificate   for   shares   of   Common   Stock

issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by

this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its

transfer   agent   in   transferring   (or   issuing)   (electronically   or   in   certificated   form)   any   certificate   for

shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this

Note   as   and   when   required   by   this   Note,   or   fails   to   remove   (or   directs   its   transfer   agent   not   to

11

Convertible Note PRLX, T1, 2019-02-27



remove   or   impairs,   delays,   and/or   hinders   its   transfer   agent   from   removing)   any   restrictive   legend

(or   to   withdraw   any stop   transfer   instructions   in   respect   thereof)   on   any certificate   for   any shares   of

Common   Stock   issued   to   the   Holder   upon   conversion   of   or   otherwise   pursuant   to   this   Note   as   and

when required by this Note (or makes any written announcement, statement or threat that it does not

intend   to   honor   the   obligations   described   in   this   paragraph)   and   any   such   failure   shall   continue

uncured   (or   any   written   announcement,   statement   or   threat   not   to   honor   its   obligations   shall   not   be

rescinded   in   writing)   for   three   (3)   business   days   after   the   Holder   shall   have   delivered   a   Notice   of

Conversion.   It   is   an   obligation   of   the   Borrower   to   remain   current   in   its   obligations   to   its   transfer

agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or

frustrated due to a balance owed by the Borrower to its transfer agent.   If at the option of the Holder,

the   Holder   advances   any   funds   to   the   Borrower s   transfer   agent   in   order   to   process   a   conversion,

such   advanced   funds   shall   be   paid   by the   Borrower   to   the   Holder   within   forty   eight   (48)   hours   of   a

demand from the Holder.

3.3.

Breach   of   Covenants.   The   Borrower   breaches   any   material   covenant   or   other

material   term   or   condition   contained   in   this   Note   and   any   collateral   documents   including   but   not

limited   to   the   Purchase   Agreement   and   such   breach   continues   for   a   period   of   three   (3)   days   after

written notice (via email) thereof to the Borrower from the Holder.

3.4.

Breach   of Representations and Warranties. Any representation or   warranty of

the   Borrower   made   herein   or   in   any agreement,   statement,   certificate,    or   any other   document   given

in   writing   pursuant   hereto   or   in   connection   herewith   (including,   without   limitation,   the   Purchase

Agreement,   and/or   the   due   diligence   questionnaire   provided   by   the   Borrower   to   the   Holder   on   or

around   the   Issue   Date),   shall   be   false   or   misleading   in   any   material   respect   when   made   and/   or   the

breach of which has (or with the passage of time will have) a material adverse effect on the rights of

the Holder with respect to this Note or the Purchase Agreement.

3.5.

Receiver   or   Trustee.   The   Borrower   or   any   subsidiary   of   the   Borrower   shall

make   an   assignment   for   the   benefit   of   creditors,   or   apply   for   or   consent   to   the   appointment   of   a

receiver   or   trustee   for   it   or   for   a   substantial   part   of   its   property   or   business,   or   such   a   receiver   or

trustee shall otherwise be appointed.

3.6.

Judgments.   Any   money   judgment,   writ   or   similar   process   shall   be   entered   or

filed   against   the   Borrower   or   any   subsidiary   of   the   Borrower   or   any   of   its   property   or   other   assets

for more than $50,000.00, and shall remain unvacated, unbonded or unstayed   for a period of twenty

(20)   days   unless   otherwise   consented   to   by   the   Holder,   which   consent   will   not   be   unreasonably

withheld.

3.7.

Bankruptcy .     Bankruptcy,     insolvency,     reorganization     or     liquidation

proceedings   or   other   proceedings,   voluntary   or   involuntary,   for   relief   under   any   bankruptcy   law   or

any   law   for   the   relief   of   debtors   shall   be   instituted   by   or   against   the   Borrower   or   any   subsidiary   of

the Borrower.

3.8.

Delisting of Common Stock. The Borrower shall fail to maintain the listing of

the  Common  Stock  on  at  least  one  of  the  OTCBB,  or  OTCQB,  or  an  equivalent  replacement

exchange, NASDAQ, the NYSE or AMEX.

3.9.

Failure   to   Comply with   the   Exchange   Act.   The   Borrower   shall   fail   to   comply

in   any   material   respect   with   the   reporting   requirements   of   the   Exchange   Act;   and/or   the   Borrower

shall cease to be subject to the reporting requirements of the Exchange Act.

12

Convertible Note PRLX, T1, 2019-02-27



3.10.       Liquidation.  Any   dissolution,   liquidation,   or   winding   up   of   Borrower   or   any

substantial portion of its business.

3.11.       Cessation    of    Operations.  Any    cessation    of    operations    by    Borrower    or

Borrower  admits  it  is  otherwise  generally  unable  to  pay  its  debts  as  such  debts  become  due,

provided,   however,   that   any   disclosure   of   the   Borrower s   ability   to   continue   as   a   going   concern

shall not be an admission that the Borrower cannot pay its debts as they become due.

3.12.       Maintenance  of  Assets.  The  failure  by   Borrower,  during  the  term  of  this

Note,   to   maintain   any   material   intellectual   property   rights,   personal,   real   property   or   other   assets

which are necessary to conduct its business (whether now or in the future).

3.13.       Financial    Statement    Restatement.  The    restatement    of    any    financial

statements   filed   by   the   Borrower   with   the   SEC   for   any   date   or   period   from   two   years   prior   to   the

Issue Date of this Note   and until this Note is no longer outstanding, if the   result of such   restatement

would,   by   comparison   to   the   unrestated   financial   statement,   have   constituted   a   material   adverse

effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

3.14.       Reverse Splits. The Borrower effectuates a reverse split of its Common Stock

without twenty (20) days prior written notice to the Holder.

3.15.       Replacement   of   Transfer   Agent.   In   the   event   that   the   Borrower   proposes   to

replace    its    transfer    agent,    the    Borrower    fails    to    provide,    prior    to    the    effective    date    of    such

replacement,    a    fully    executed    Irrevocable    Transfer    Agent    Instructions    in    a    form    as    initially

delivered    pursuant    to    the    Purchase    Agreement    (including    but    not    limited    to    the    provision    to

irrevocably   reserve   shares   of   Common   Stock   in   the   Reserved   Amount)   signed   by   the   successor

transfer agent to Borrower and the Borrower.

3.16.       Cross-Default.  Notwithstanding  anything  to  the  contrary  contained  in  this

Note   or   the   other   related   or   companion   documents,   a   breach   or   default   by   the   Borrower   of   any

covenant   or   other   term   or   condition   contained   in   any   of   the   Other   Agreements,   after   the   passage   of

all   applicable   notice   and   cure   or   grace   periods,   shall,   at   the   option   of   the   Holder,   be   considered   a

default   under   this   Note   and   the   Other   Agreements,   in   which   event   the   Holder   shall   be   entitled   (but

in no event required) to apply all rights and remedies of the Holder under the terms of this Note and

the   Other   Agreements   by   reason   of   a   default   under   said   Other   Agreement   or   hereunder. Other

Agreements   means,   collectively,   all   agreements   and   instruments   between,   among   or   by:   (1)   the

Borrower,  and,   or   for   the   benefit   of,   (2)   the   Holder   and   any   affiliate   of   the   Holder,   including,

without   limitation,   promissory   notes;   provided,   however,   the   term   Other   Agreements   shall   not

include   the   related   or   companion   documents   to   this   Note.   Each   of   the   loan   transactions   will   be

cross-defaulted  with  each  other  loan  transaction  and  with  all  other  existing   and  future  debt  of

Borrower to the Holder.

Upon   the   occurrence   and   during   the   continuation   of   any Event   of   Default   specified   in   Article   III   of

the   Note   exercisable   through   the   delivery   of   written   notice   to   the   Borrower   by   such   Holders   (the

Default   Notice ),   the   Note   shall   become   immediately due   and   payable   and   the   Borrower   shall   pay

to   the   Holder,   in   full   satisfaction   of   its   obligations   hereunder,   an   amount   equal   to   the   greater   of   (i)

200% times the   sum of   (w)   the   then   outstanding   principal   amount   of   this   Note plus (x)   accrued   and

unpaid   interest   on   the   unpaid   principal   amount   of   this   Note   to   the   date   of   payment   (the   Mandatory

Repayment   Date ) plus ( y)   Default   Interest,   if   any,   on   the   amounts   referred   to   in   clauses   (w)   and/or

(x) plus ( z)  any  amounts  owed  to  the  Holder  pursuant  to  Section  and  1.4(g)  hereof  (the  then

outstanding   principal   amount   of   this   Note   to   the   date   of   payment plus t he   amounts   referred   to   in

13

Convertible Note PRLX, T1, 2019-02-27



clauses   (x),   (y)   and   (z)   shall   collectively   be   known   as   the   Default   Sum )   or   (ii)   the   parity   value

of   the   Default   Sum   to   be   prepaid,   where   parity   value   means   (a)   the   highest   number   of   shares   of

Common    Stock    issuable    upon    conversion    of    or    otherwise    pursuant    to    such    Default    Sum    in

accordance    with    Article    I,    treating    the    Trading    Day    immediately    preceding    the    Mandatory

Repayment  Date  as  the   Conversion  Date  for  purposes  of  determining  the  lowest  applicable

Conversion   Price,   unless   the   Default   Event   arises   as   a   result   of   a   breach   in   respect   of   a   specific

Conversion   Date   in   which   case   such   Conversion   Date   shall   be   the   Conversion   Date), multiplied

by (b)   the   highest   Closing   Price   for   the   Common   Stock   during   the   period   beginning   on   the   date   of

first occurrence of the Event of Default and ending one day prior to the Mandatory Repayment Date

(the Default Amount ) and all other amounts payable hereunder shall immediately become due and

payable,  all  without  demand,   presentment  or   notice,   all  of   which   hereby   are   expressly   waived,

together   with   all   costs,   including,   without   limitation,   legal   fees   and   expenses,   of   collection,   and   the

Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

If   the   Borrower   fails   to   pay the   Default   Amount   within   five   (5)   business   days   of   written   notice   that

such   amount   is   due   and   payable,   then   the   Holder   shall   have   the   right   at   any   time,   so   long   as   the

Borrower   remains   in   default   (and   so   long   and   to   the   extent   that   there   are   sufficient   authorized

shares),   to   require   the   Borrower,   upon   written   notice,   to   immediately   issue,   in   lieu   of   the   Default

Amount,   the   number   of   shares   of   Common   Stock   of   the   Borrower   equal   to   the   Default   Amount

divided   by   the   Conversion   Price   then   in   effect.     The   Holder   may   still   convert   any   amounts   due

hereunder,   including   without   limitation   the   Default   Sum,   until   such   time   as   this   Note   has   been

repaid in full.

3.17.   Inside  Information.     The   Borrower   or   its   officers,   directors,   and/or   affiliates

attempt   to   transmit,   convey,   disclose,   or   any   actual   transmittal,   conveyance,   or   disclosure   by   the

Borrower   or   its   officers,   directors,   and/or   affiliates   of,   material   non-public   information   concerning

the  Borrower,  to  the  Holder  or  its  successors  and  assigns,  which  is  not  immediately   cured  by

Borrower s filing of a Form 8-K pursuant to Regulation FD on that same date.

3.18   Bid  Price .    The  Borrower  shall  lose  the   bid price  for  its  Common  Stock

($0.0001  on  the   Ask  with  zero  market  makers  on  the   Bid  per  Level  2)  and/or  a  market

(including the OTC Pink, OTCQB or an equivalent replacement exchange).

3.  19   Market  Loss.  If  at  any   time  while  this  Note  is  outstanding   the  Borrower s

Common   Stock   trades   below   $0.01   for   five   (5)   consecutive   Trading   Days,   the   principal   amount   of

the   Note   shall   automatically   and   without   further   action   increase   by   twenty-five   thousand   dollars

($25,000.00),   and   at   the   sole   option   of   the   Holder,   the   Company   shall   within   fifteen   (15)   calendars

days from Holder s direction to so, obtain the necessary shareholder and board of director approvals

(if applicable), and file the requisite documents with FINRA, to effectuate a reverse split.

ARTICLE IV. MISCELLANEOUS

4.1.

Failure   or   Indulgence   Not   Waiver.   No   failure   or   delay   on   the   part   of   the

Holder   in   the   exercise   of   any   power,   right   or   privilege   hereunder   shall   operate   as   a   waiver   thereof,

nor shall any single or partial exercise of any such power, right or privilege preclude other or further

exercise    thereof    or    of    any  other    right,    power    or    privileges.    All    rights    and    remedies    existing

hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

4.2.

Notices.    All    notices,    demands,    requests,    consents,    approvals,    and    other

communications   required   or   permitted   hereunder   shall   be   in   writing   and,   unless   otherwise   specified

herein, shall be   (i) personally served,   (ii) deposited in the mail, registered   or certified,   return   receipt

14

Convertible Note PRLX, T1, 2019-02-27



requested,   postage   prepaid,   (iii)   delivered   by   reputable   air   courier   service   with   charges   prepaid,   or

(iv)   transmitted   by   hand   delivery,   telegram,   email   or   facsimile,   addressed   as   set   forth   below   or   to

such   other   address   as   such   party shall   have   specified   most   recently by written   notice.   Any notice   or

other   communication   required   or   permitted   to   be   given   hereunder   shall   be   deemed   effective   (a)

upon   hand   delivery   or   delivery   by   facsimile   or   email,   with   accurate   confirmation   generated   by   the

transmitting   facsimile   machine   or  computer,  at  the   address,  email  or   number   designated  in  the

Purchase   Agreement  (if  delivered   on  a   business  day   during   normal  business  hours  where   such

notice is to be received), or the first business day following such delivery (if delivered other than on

a   business   day   during   normal   business   hours   where   such   notice   is   to   be   received)   or   (b)   on   the

second    business    day  following  the    date    of    mailing  by  express    courier    service,    fully  prepaid,

addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.

4.3.

Amendments.   This   Note   and   any   provision   hereof   may   only   be   amended   by

an   instrument   in   writing signed   by the   Borrower   and   the   Holder.   The   term   Note   and   all   reference

thereto,   as   used   throughout   this   instrument,   shall   mean   this   instrument   (and   the   other   Notes   issued

pursuant   to   the   Purchase   Agreement)   as   originally   executed,   or   if   later   amended   or   supplemented,

then as so amended or supplemented.

4.4.

Assignability .    This    Note    shall    be    binding    upon    the    Borrower    and    its

successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns.

Each transferee of this Note must be an accredited investor (as defined in Rule 501(a) of the 1933

Act).   Notwithstanding   anything   in   this   Note   to   the   contrary,   this   Note   may   be   pledged   as   collateral

in connection with a bona fide margin account or other lending arrangement.

4.5.

Cost  of  Collection .  If  default  is  made  in  the  payment  of  this  Note,  the

Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys fees.

4.6.

Governing Law . This   Note shall be   governed by and construed   in accordance

with   the   laws   of   the   State   of   Nevada   without   regard   to   conflicts   of   laws   principles   that   would   result

in the application of the substantive laws of another jurisdiction.  Any action brought by either party

against   the   other   concerning the transactions   contemplated   by this   Agreement   must   be   brought   only

in   the   civil   or   state   courts   of   New   York   or   in   the   federal   courts   located   in   the   State   and   county   of

New York.  Both parties   and the individual signing this Agreement on behalf of the   Borrower   agree

to   submit   to   the   jurisdiction   of   such   courts.  The   prevailing   party   shall   be   entitled   to   recover   from

the   other   party its   reasonable   attorney s   fees   and   costs.  In   the   event   that   any provision   of   this   Note

is   invalid   or   unenforceable   under   any   applicable   statute   or   rule   of   law,   then   such   provision   shall   be

deemed   inoperative   to   the   extent   that   it   may   conflict   therewith   and   shall   be   deemed   modified   to

conform    with    such    statute    or    rule    of    law.    Any    such    provision    which    may    prove    invalid    or

unenforceable   under   any   law   shall   not   affect   the   validity or   unenforceability of   any other   provision

of   this   Note.   Nothing   contained   herein   shall   be   deemed   or   operate   to   preclude   the   Holder   from

bringing suit   or   taking other   legal   action   against   the   Borrower   in   any other   jurisdiction   to collect   on

the   Borrower s   obligations   to   Holder,   to   realize   on   any   collateral   or   any   other   security   for   such

obligations,   or   to   enforce   a   judgment   or   other   decision   in   favor   of   the   Holder.  This   Note   shall   be

deemed  an  unconditional  obligation  of  Borrower  for  the  payment  of  money  and,  without

limitation   to   any   other   remedies   of   Holder,   may   be   enforced   against   Borrower   by   summary

proceeding pursuant to New York Civil Procedure Law and Rules Section 3213 or any similar

rule   or   statute   in   the   jurisdiction   where   enforcement   is   sought.  For   purposes   of   such   rule   or

statute, any other document or agreement to which Holder and Borrower are parties or which

15

Convertible Note PRLX, T1, 2019-02-27



Borrower   delivered   to   Holder,   which   may   be   convenient   or   necessary   to   determine   Holder s

rights hereunder or Borrower s obligations to Holder are deemed a part of   this Note, whether

or   not   such   other   document   or   agreement   was   delivered   together   herewith   or   was   executed

apart from this Note.

4.7.

Certain Amounts. Whenever pursuant to this Note the Borrower is required to

pay   an   amount   in   excess   of   the   outstanding   principal   amount   (or   the   portion   thereof   required   to   be

paid  at  that  time)  plus  accrued  and  unpaid  interest  plus  Default  Interest  on  such  interest,  the

Borrower   and   the   Holder   agree   that   the   actual   damages   to   the   Holder   from   the   receipt   of   cash

payment   on   this   Note   may   be   difficult   to   determine   and   the   amount   to   be   so   paid   by   the   Borrower

represents stipulated damages and not a penalty and is intended to compensate the Holder in part for

loss   of   the   opportunity to   convert   this   Note   and   to   earn   a   return   from   the   sale   of   shares   of   Common

Stock   acquired   upon   conversion   of   this   Note   at   a   price   in   excess   of   the   price   paid   for   such   shares

pursuant   to   this   Note.   The   Borrower   and   the   Holder   hereby   agree   that   such   amount   of   stipulated

damages   is   not   plainly disproportionate   to   the   possible   loss   to   the   Holder   from   the   receipt   of   a   cash

payment without the opportunity to convert this Note into shares of Common Stock.

4.8.

Disclosure .    Upon    receipt    or    delivery    by  the    Company    of    any    notice    in

accordance   with   the   terms   of   this   Note,   unless   the   Company   has   in   good   faith   determined   that   the

matters   relating   to   such   notice   do   not   constitute   material,   non-public   information   relating   to   the

Company   or   any   of   its   Subsidiaries,   the   Company   shall   within   four   (4)   Trading   Day   after   any   such

receipt   or   delivery,   publicly   disclose   such   material,   non-public   information   on   a   Current   Report   on

Form 8-K or otherwise.   In the event that the Company believes that a notice contains material, non-

public information relating to the Company or any of its Subsidiaries, the Company so shall indicate

to   such   Holder   contemporaneously   with   delivery   of   such   notice,   and   in   the   absence   of   any   such

indication,   the   Holder   shall   be   allowed   to   presume   that   all   matters   relating   to   such   notice   do   not

constitute material, non-public information relating to the Company or its Subsidiaries.

4.9.

Notice   of   Corporate   Events.   Except   as   otherwise   provided   below,   the   Holder

of   this   Note   shall   have   no   rights   as   a   Holder   of   Common   Stock   unless   and   only to   the   extent   that   it

converts    this    Note    into    Common    Stock.    The    Borrower    shall    provide    the    Holder    with    prior

notification of any meeting of the   Borrower s shareholders (and copies of   proxy materials and other

information   sent   to   shareholders).   In   the   event   of   any   taking   by   the   Borrower   of   a   record   of   its

shareholders for the purpose of determining shareholders who are entitled to receive payment of any

dividend   or   other   distribution,   any   right   to   subscribe   for,   purchase   or   otherwise   acquire   (including

by   way   of   merger,   consolidation,   reclassification   or   recapitalization)   any   share   of   any   class   or   any

other  securities  or  property,  or  to  receive  any  other  right,  or  for  the  purpose  of  determining

shareholders   who   are   entitled   to   vote   in   connection   with   any proposed   sale,   lease   or   conveyance   of

all   or   substantially   all   of   the   assets   of   the   Borrower   or   any   proposed   liquidation,   dissolution   or

winding   up   of   the   Borrower,   the   Borrower   shall   mail   a   notice   to   the   Holder,   at   least   twenty   (20)

days   prior   to   the   record   date   specified   therein   (or   thirty   (30)   days   prior   to   the   consummation   of   the

transaction   or   event,   whichever   is   earlier),   of   the   date   on   which   any   such   record   is   to   be   taken   for

the   purpose   of   such   dividend,   distribution,   right   or   other   event,   and   a   brief   statement   regarding   the

amount and character of such dividend, distribution, right or other event to the extent known at such

time.   The   Borrower   shall   make   a   public   announcement   of   any   event   requiring   notification   to   the

Holder   hereunder   substantially   simultaneously   with   the   notification   to   the   Holder   in   accordance

with the terms of this Section 4.9.

16

Convertible Note PRLX, T1, 2019-02-27



4.10.       Remedies.   The   Borrower   acknowledges   that   a   breach   by   it   of   its   obligations

hereunder   will   cause   irreparable   harm   to   the   Holder,   by   vitiating   the   intent   and   purpose   of   the

transaction   contemplated   hereby.   Accordingly,   the   Borrower   acknowledges   that   the   remedy   at   law

for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach

or  threatened  breach  by  the  Borrower  of  the  provisions  of  this  Note,  that  the  Holder  shall  be

entitled,  in  addition  to  all  other  available  remedies  at  law  or  in  equity,  and  in  addition  to  the

penalties   assessable   herein,   to   an   injunction   or   injunctions   restraining,   preventing   or   curing   any

breach  of  this  Note  and  to  enforce  specifically  the  terms  and  provisions  thereof,  without  the

necessity of showing economic loss and without any bond or other security being required.

4.11.       Usury .   This   Note   shall   be   subject   to   the   anti-usury   limitations   contained   in

the Purchase Agreement.

(Remainder of Page intentionally left blank)

17

Convertible Note PRLX, T1, 2019-02-27



IN WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly

authorized officer as of the Issue Date first set forth above.

PARALLAX HEALTH SCIENCES, INC.

By:

Name: Paul R. Arena

Title: CEO

18

Convertible Note PRLX, T1, 2019-02-27



EXHIBIT A

NOTICE OF CONVERSION

The    undersigned    hereby  elects    to    convert    principal    under    the    12%    Convertible    Note    of  PARALLAX    HEALTH

SCIENCES,   INC.,   a   Nevada   corporation   (the   Company ),   into   shares   of   common   stock   (the   Common   Stock ),   of   the

Company   according   to   the   conditions   hereof,   as   of   the   date   written   below.    If   shares   of   Common   Stock   are   to   be   issued

in   the   name   of   a   person   other   than   the   undersigned,   the   undersigned   will   pay   all   transfer   taxes   payable   with   respect

thereto   and   is delivering herewith such certificates and   opinions as reasonably requested   by the   Company in accordance

therewith.     No   fee   will   be   charged   to   the   holder   for   any   conversion,   except   for   such   transfer   taxes,   if   any.   By   the

delivery of this Notice   of Conversion   the   undersigned   represents and   warrants to   the   Company that   its ownership   of   the

Common Stock does not exceed the amounts specified under Section 1.1 of this Note, as determined in accordance   with

Section   13(d)   of   the   Exchange   Act.   The   undersigned   agrees   to   comply   with   the   prospectus   delivery requirements   under

the   applicable   securities   laws   in   connection   with   any transfer   of   the   aforesaid   shares   of   Common   Stock   pursuant   to   any

prospectus.

Conversion calculations:

Issue Date of Note:

Date to Effect Conversion:

Conversion Price:

Principal Amount of Note to be Converted:

Less applicable fees under the Note:

Amount of Note to be Converted:

Interest Amount to be Converted:

Less applicable fees under the Note:

Amount of Note to be Converted:

Additional Principal on Account of Conversion

Pursuant to Section 1.2(b) of the Note:

Number of shares of Common Stock to be issued:

Remaining Principal Balance of Note:

Signature:

Name:

Address for Delivery of Common Stock Certificates:

Or

DWAC Instructions:

DTC No:

Account No:

19

Convertible Note PRLX, T1, 2019-02-27



SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (this Agreement ), dated as of February

27,   2019,   is   entered   into   by   and   between PARALLAX   HEALTH   SCIENCES,   INC.,   a   Nevada

corporation   (the   Company ),   and   EMA   Financial,   LLC,   a   Delaware   limited   liability   company

(the Purchaser ).

WHEREAS,   subject   to   the   terms   and   conditions   set   forth   in   this   Agreement   and   pursuant

to Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act or 1933 Act ),

and Rule 506 promulgated thereunder by the United States Securities and Exchange Commission

(the SEC ), the Company desires to issue and sell to the Purchaser, and the Purchaser desires to

purchase from the Company a 12% Convertible Note of the Company, in the form attached hereto

as  Exhibit  A,  in  the  principal  amount  of  $111,000.00  (together  with  any  note(s)  issued  in

replacement thereof or as interest thereon or otherwise with respect thereto in accordance with the

terms  thereof,   the   Note ),  convertible  into   shares  ( Conversion   Shares )   of  common   stock,

$0.001 par value per share (the Common Stock ), of the Company, upon the terms and subject to

the limitations and conditions set forth in such Note.

NOW,   THEREFORE,   IN   CONSIDERATION   of   the   mutual   covenants   contained   in   this

Agreement, and for other good and valuable consideration, the receipt and adequacy of which are

hereby acknowledged, the Company and the Purchaser agree as follows:

1.    Purchase and Sale of Note.

a)

Purchase   of   Note .   On   the   Closing   Date   (as   defined   below),   the   Company

shall issue and sell to the Purchaser, and the Purchaser agrees to purchase from the Company, the

Note for an aggregate purchase price of $104,340.00 ( Purchase Price ). Further, Company shall

issue warrants to Buyer to purchase 300,000 shares of common stock (the Warrant ).

b)

Form   of   Payment.   On   the   Closing   Date   (i)   the   Purchaser   shall   pay   the

Purchase   Price   by   wire   transfer   of   immediately   available   funds   to   the   Company,   in   accordance

with   the   Company s   written   wiring   instructions,   simultaneously   with   delivery   of   the   Note,   and

(ii)  the  Company   shall  deliver  such  Note  duly  executed  on  behalf  of  the  Company  to  the

Purchaser, simultaneously with delivery of such Purchase Price.

c)

Closing    Date .    Subject    to    the    satisfaction    (or    written    waiver)    of    the

conditions   thereto   set   forth   in   Section   8   and   Section   9   below,   the   closing   of   the   transactions

contemplated   by this   Agreement   (the   Closing )   shall   occur   on   the   first   business   day following

the date hereof or such other mutually agreed upon time (the Closing Date )

2.    Purchaser s   Representations   and   Warranties. T he   Purchaser   represents   and

warrants to the Company that:

a)

Investment   Purpose .   Purchaser   is   acquiring   the   Note,   the   Warrant,   and   the

Conversion   Shares  (collectively,   the   Securities )  for   its  own  account  and   not  with   a   view

towards,   or   for   resale   in   connection   with,   the   public   sale   or   distribution   thereof   in   violation   of

applicable   securities   laws;   provided,   however,   by   making   the   representations   herein,   Purchaser

does   not   agree,   or   make   any   representation   or   warranty,   to   hold   any   of   the   Securities   for   any

1

SPA PRLX, T1, 2019-02-27



minimum or other specific term and reserves the   right to dispose of the Securities at any time in

accordance with or pursuant to a registration statement or an exemption under the 1933 Act.  The

Purchaser  is  acquiring  the  Securities  hereunder  in  the  ordinary  course  of  its  business.  The

Purchaser   does   not   presently   have   any   agreement   or   understanding,   directly   or   indirectly,   with

any person to distribute any of the Securities in violation of applicable securities laws.

b)

Accredited Investor Status. The Purchaser is an accredited investor as that

term is defined in Rule 501(a) of Regulation D (an Accredited Investor ).

3.    Representations  and  Warranties  of  the  Company .  Except  as  disclosed  by  the

Company   in   the   publicly   filed   SEC   Documents   the   Company   represents   and   warrants   to   the

Purchaser, as of the date hereof and the Closing Date, that:

a)

Organization and Qualification. The Company and each of its Subsidiaries

(as defined below), if any, is a corporation duly organized, validly existing and in good standing

under   the   laws   of   the   jurisdiction   in   which   it   is   incorporated,   with   full   power   and   authority

(corporate and other) to   own, lease, use   and operate its properties and to carry on its business as

and where now owned, leased, used, operated and conducted. The SEC Documents set forth a list

of all of the   Subsidiaries   of the Company and   the   jurisdiction in which each is incorporated The

Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business and

is in good standing in every jurisdiction in which its ownership or use of property or the nature of

the business conducted by it makes such qualification necessary except where the failure to be so

qualified   or   in   good   standing   would   not   have   a   Material   Adverse   Effect.   Material   Adverse

Effect means any material adverse effect on the business, operations, assets, financial condition

or   prospects   of   the   Company or   its   Subsidiaries,   if   any,   taken   as   a   whole,   or   on   the   transactions

contemplated  hereby   or  by   the  agreements  or  instruments  to  be  entered  into  in  connection

herewith.    Subsidiaries   means   any   corporation   or   other   organization,   whether   incorporated   or

unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership

interest.

b)

Authorization;   Enforcement.   (i)   The   Company   has   all   requisite   corporate

power   and authority to   enter into and   perform this Agreement, the   Note,   and the Warrant and to

consummate   the   transactions   contemplated   hereby   and   thereby   and   to   issue   the   Securities,   in

accordance with the   terms hereof and   thereof, (ii)   the execution and delivery of this Agreement,

the   Note,   and   the   Warrant   by   the   Company   and   the   consummation   by   it   of   the   transactions

contemplated   hereby   and   thereby   (including   without   limitation,   the   issuance   of   the   Note,   and

Warrant   and   the   issuance   and   reservation   for   issuance   of   the   Conversion   Shares,   and   Warrant

Shares (as defined in the Warrant) issuable upon conversion and exercise thereof) have been duly

authorized   by   the   Company s   Board   of   Directors   and   no   further   consent   or   authorization   of   the

Company,   its   Board   of   Directors,   or   its   shareholders   is   required,   (iii)   this   Agreement   has   been

duly executed and delivered by the Company by its authorized representative, and such authorized

representative is the true and official representative with authority to sign this Agreement and the

other   documents   executed   in   connection   herewith   and   bind   the   Company   accordingly,   and   (iv)

this  Agreement  constitutes,   and   upon   execution   and   delivery   by   the   Company   of   the   Note,

Warrant, and each of such instruments will constitute, a legal, valid and binding obligation of the

Company enforceable against the Company in accordance with its terms.

2

SPA PRLX, T1, 2019-02-27



c)

Capitalization .   As   of   the   date   hereof,   the   authorized   capital   stock   of   the

Company,   and   number   of   shares   issued   and   outstanding,   is   as   set   forth   in   the   Company s   most

recent   periodic   report   filed   with   the   SEC.   Except   as   disclosed   in   the   SEC   Documents   no   shares

are   reserved   for   issuance   pursuant   to   the   Company s   stock   option   plans.   Except   as   disclosed   in

the SEC Documents no shares are reserved for issuance pursuant to securities exercisable for, or

convertible into or exchangeable for shares of Common Stock. All of such outstanding shares of

capital   stock   are,   or   upon   issuance   will   be,   duly   authorized,   validly   issued,   fully   paid   and   non-

assessable.   No   shares   of   capital   stock   of   the   Company   are   subject   to   preemptive   rights   or   any

other   similar   rights   of   the   shareholders   of   the   Company   or   any   liens   or   encumbrances   imposed

through the   actions or failure to act of the Company. As of the effective date of this Agreement,

and   except   as   disclosed   in   the   SEC   Documents,   (i)   there   are   no   outstanding   options,   warrants,

scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements, understandings, claims

or   other   commitments   or   rights   of   any   character   whatsoever   relating   to,   or   securities,   notes   or

rights convertible into or exchangeable for any shares of capital stock of the Company or any of

its   Subsidiaries,   or   arrangements   by   which   the   Company   or   any   of   its   Subsidiaries   is   or   may

become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries,

(ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries

is   obligated   to   register   the   sale   of   any of   its   or   their   securities   under   the   1933   Act   and   (iii)   there

are  no  anti-dilution  or  price  adjustment  provisions  contained  in  any   security  issued  by  the

Company (or in any agreement providing rights to   security holders) that will be triggered by the

issuance   of   any   of   the   Securities.   The   Company   has   furnished   to   the   Purchaser   true   and   correct

copies   of   the   Company s   Certificate   or   Articles   of   Incorporation   as   in   effect   on   the   date   hereof

( Formation   Documents ),   the   Company s   By-laws,   as   in   effect   on   the   date   hereof   (the   By-

laws ),   and   the   terms   of   all   securities   convertible   into   or   exercisable   for   Common   Stock   of   the

Company and the material rights of the holders thereof in respect thereto.

d)

Issuance of Shares. The Conversion Shares, and Warrant Shares (as defined

in the Warrant)   are duly authorized and reserved for issuance   and, upon   conversion of the   Note,

and exercise of the Warrant respectively, as the case may be, in accordance with their respective

terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims

and encumbrances with respect to the issue   thereof and shall not be subject   to preemptive   rights

or other similar rights of shareholders of the Company and will not impose personal liability upon

the holder thereof.

e)

Acknowledgment    of    Dilution.    The    Company s    executive    officers    and

directors understand the nature of the Securities being sold hereby and recognize that the issuance

of the Securities will have a potential dilutive effect on the equity holdings of other holders of the

Company s   equity   or   rights   to   receive   equity   of   the   Company.  The   Board   of   Directors   of   the

Company has concluded, in its good faith business judgment that the issuance of the Securities is

in the best interests of the Company.  The Company specifically acknowledges that its obligation

to   issue   the   Conversion   Shares   upon   conversion   of   the   Notes   is   binding   upon   the   Company and

enforceable regardless of the dilution such issuance may have on the ownership interests of other

stockholders of the Company or parties entitled to receive equity of the Company.

f)

No Conflicts. The execution, delivery and performance of this Agreement,

the   Note,   and   the   Warrant   by   the   Company   and   the   consummation   by   the   Company   of   the

transactions   contemplated   hereby   and   thereby   (including,   without   limitation,   the   issuances   and

3

SPA PRLX, T1, 2019-02-27



reservations for issuance of the Conversion Shares, and Warrant Shares) will not (i) conflict with

or result in a violation of any provision of the Formation Documents or By-laws, or (ii) violate or

conflict with, or result in a breach of any provision of, or constitute a default (or an event which

with notice or lapse of time or both could become a default) under, or give to others any rights of

termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent

license   or   instrument   to   which   the   Company   or   any   of   its   Subsidiaries   is   a   party   and   that   is   not

filed   as   an   SEC   Document   or   other   document   filed   with   the   SEC,   or   (iii)   result   in   a   violation   of

any   law,   rule,   regulation,   order,   judgment   or   decree   (including   federal   and   state   securities   laws

and regulations and regulations of any self-regulatory organizations to which the Company or its

securities   are   subject)   applicable   to   the   Company   or   any   of   its   Subsidiaries   or   by   which   any

property or asset of the Company or any of its Subsidiaries is bound or affected (except for such

conflicts,  defaults,  terminations,  amendments,  accelerations,  cancellations  and  violations  as

would  not,  individually  or  in  the  aggregate,  have  a  Material  Adverse  Effect).  Neither  the

Company nor any of its Subsidiaries is in violation of its Formation Documents, By-laws or other

organizational documents and neither the Company nor   any of   its Subsidiaries is in default (and

no   event   has   occurred   which   with   notice   or   lapse of   time   or   both   could put the   Company or   any

of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken

any   action   or   failed   to   take   any   action   that   would   give   to   others   any   rights   of   termination,

amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the

Company or any of its Subsidiaries is a party or by which any property or assets of the Company

or  any  of  its  Subsidiaries  is  bound  or  affected,  except  for  possible  defaults  as  would  not,

individually or in the aggregate, have a Material Adverse Effect. The businesses of the Company

and   its   Subsidiaries,   if   any,   are   not   being   conducted,   and   shall   not   be   conducted   so   long   as   the

Purchaser   owns   any   of   the   Securities,   in   violation   of   any   law,   ordinance   or   regulation   of   any

governmental   entity.   Except   as   specifically   contemplated   by   this   Agreement   and   as   required

under the 1933 Act and any applicable state securities laws, the Company is not required to obtain

any  consent,  authorization  or  order  of,  or  make  any  filing  or  registration  with,  any  court,

governmental agency, regulatory agency, self-regulatory organization or stock market or any third

party in order for it to execute, deliver or perform any of its obligations under this Agreement and

the   Note   in   accordance   with   the   terms   hereof   or   thereof   or   to   issue   and   sell   the   Securities   in

accordance   with   the   terms   hereof   and   thereof   and   to   issue   the   Conversion   Shares.   All   consents,

authorizations, orders, filings and registrations which the Company is required to obtain pursuant

to   the   preceding   sentence   have   been   obtained   or   effected   on   or   prior   to   the   date   hereof.   The

Company   is   not   in   violation   of   the   listing   requirements   of   the   Over-the-Counter   Bulletin   Board

(the OTCBB ), or OTCQB, and   does not reasonably anticipate that the   Common Stock will be

delisted by the OTCBB, or OTCQB, in the foreseeable future. The Company and its Subsidiaries

are unaware of any facts or circumstances which might give rise to any of the foregoing.

g)

SEC Documents; Financial Statements. The Company has filed all reports,

schedules,   forms,   statements   and   other   documents   required   to   be   filed   by it   with   the SEC   (all   of

the  foregoing  filed  prior  to  the  date  hereof  and  all  exhibits  included  therein  and  financial

statements    and    schedules    thereto    and    documents    (other    than    exhibits    to    such    documents)

incorporated by reference therein, being hereinafter referred to herein as the SEC Documents ).

Upon written request the   Company will deliver to the Purchaser true   and complete copies of the

SEC   Documents,   except   for   such   exhibits   and   incorporated   documents.   As   of   their   respective

dates,  the  SEC  Documents  complied  in  all  material  respects  with  the  requirements  of  the

Securities Exchange Act of 1934, as amended ( 1934 Act or Exchange   Act ), and none of the

4

SPA PRLX, T1, 2019-02-27



SEC   Documents,   at   the   time   they   were   filed   with   the   SEC,   contained   any   untrue   statement   of   a

material fact or omitted to state a material fact required to be stated therein or necessary in order

to   make   the   statements   therein,   in   light   of   the   circumstances   under   which   they   were   made,   not

misleading.   None   of   the   statements   made   in   any such   SEC   Documents   is,   or   has   been,   required

to be amended or updated under applicable law (except for such statements as have been amended

or updated in subsequent   filings prior the date hereof). As of their respective dates, the financial

statements   of   the   Company included   in   the   SEC   Documents   complied   as   to   form   in   all   material

respects   with   applicable   accounting   requirements   and   the   published   rules   and   regulations   of   the

SEC   with   respect   thereto.   Such   financial   statements   have   been   prepared   in   accordance   with

United   States   generally   accepted   accounting   principles,   consistently applied,   during   the   periods

involved   and   fairly   present   in   all   material   respects   the   consolidated   financial   position   of   the

Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of

their   operations   and   cash   flows   for   the   periods   then   ended   (subject,   in   the   case   of   unaudited

statements, to normal year-end audit adjustments). Except as set forth in the financial statements

of   the   Company included   in   the   SEC   Documents,   the   Company has   no   liabilities,   contingent   or

otherwise, other than (i) liabilities incurred in the ordinary course of business, and (ii) obligations

under   contracts   and   commitments   incurred   in   the   ordinary   course   of   business   and   not   required

under generally accepted accounting principles to be reflected in such financial statements, which,

individually or in the aggregate, are not material to the financial condition or operating results of

the Company. The Company is subject to the reporting requirements of the 1934 Act.

h)

Absence   of   Certain   Changes.   Except   as   disclosed   in   the   SEC   filings,   there

has been no material adverse change and no material adverse development in the assets, liabilities,

business, properties, operations, financial condition, results of operations, prospects or 1934 Act

reporting status of the Company or any of its Subsidiaries.

i)

Absence   of   Litigation.   Except   as   disclosed   in   the   SEC   filings,   there   is   no

action,   suit,   claim,   proceeding,   inquiry   or   investigation   before   or   by   any   court,   public   board,

government   agency,   self-regulatory   organization   or   body   pending   or,   to   the   knowledge   of   the

Company   or   any   of   its   Subsidiaries,   threatened   against   or   affecting   the   Company   or   any   of   its

Subsidiaries,   or   their   officers   or   directors   in   their   capacity   as   such,   that   could   have   a   Material

Adverse Effect. The public filings contain a complete list and summary description of any pending

or, to the knowledge of the Company, threatened proceeding against or affecting the Company or

any of   its   Subsidiaries,   without   regard   to   whether   it   would   have   a   Material   Adverse   Effect.   The

Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to

any of the foregoing.

j)

Patents, Copyrights, etc . The Company and each of its Subsidiaries owns or

possesses   the   requisite   licenses   or   rights   to   use   all   patents,   patent   applications,   patent   rights,

inventions,   know-how,   trade   secrets,   trademarks,   trademark   applications,   service   marks,   service

names, trade names and copyrights ( Intellectual Property ) necessary to enable it to conduct its

business   as   now   operated   (and,   as   presently   contemplated   to   be   operated   in   the   future);   there   is

no   claim   or   action   by   any   person   pertaining   to,   or   proceeding   pending,   or   to   the   Company s

knowledge threatened, which challenges the right of the Company or of a Subsidiary with respect

to   any   Intellectual   Property necessary to   enable   it   to   conduct   its   business   as   now   operated   (and,

as presently contemplated to be operated in the future); to the best of the Company s knowledge,

the   Company s   or   its   Subsidiaries   current   and   intended   products,   services   and   processes   do   not

5

SPA PRLX, T1, 2019-02-27



infringe   on   any   Intellectual   Property   or   other   rights   held   by   any   person   and/or   entity;   and   the

Company is unaware of any facts or circumstances which might give rise to any of the foregoing.

The Company and each of its Subsidiaries have taken reasonable security measures to protect the

secrecy, confidentiality and value of their Intellectual Property.

k)

No Materially Adverse Contracts, Etc. Neither the   Company nor any of its

Subsidiaries is subject to any charter, corporate or other legal restriction, or any judgment, decree,

order,   rule   or   regulation   which   in   the   judgment   of   the   Company s   officers   has   or   is   expected   in

the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is

a   party to   any contract   or   agreement   which   in   the   judgment   of   the   Company s   officers   has   or   is

expected to have a Material Adverse Effect.

l)

Disclosure . No event or circumstance has occurred or exists with respect to

the   Company or   any of   its   Subsidiaries   or   its   or   their   business,   properties,   prospects,   operations

or financial conditions, which, under applicable law, rule or regulation, requires public disclosure

or announcement by the Company but which has not been so publicly announced or disclosed.

m)

Brokers.   The Company hereby represents and warrants that it has not hired,

retained   or   dealt   with   any   broker,   finder,   consultant,   person,   firm   or   corporation   ( Broker )   in

connection   with   the   negotiation,   execution   or   delivery   of   this   Agreement   or   the   transactions

contemplated   hereunder.   The   Company   covenants   and   agrees   that   should   any   claim   be   made

against   Purchaser   for   any   commission   or   other   compensation   by   the   Broker,   based   upon   the

Company s   engagement   of   such   person   in   connection   with   this   transaction,   the   Company   shall

indemnify, defend and hold Purchaser harmless from and against any and all damages, expenses

(including attorneys fees and disbursements) and liability arising from such claim. The Company

shall pay the commission of the Broker, to the attention of the Broker, pursuant to their separate

agreement(s) between the Company and the Broker.

n)

Permits;  Compliance .  The  Company  and  each  of  its  Subsidiaries  is  in

possession  of  all  franchises,  grants,  authorizations,  licenses,  permits,  easements,  variances,

exemptions,   consents,   certificates,   approvals   and   orders   necessary   to   own,   lease   and   operate   its

properties   and to   carry on its business as   it is now being conducted   (collectively,   the   Company

Permits ),   and   there   is   no   action   pending   or,   to   the   knowledge   of   the   Company,   threatened

regarding   suspension   or   cancellation   of   any of   the   Company Permits.   Neither   the   Company nor

any of its Subsidiaries is in conflict with, or in default or violation of, any of the Company Permits,

except for any such conflicts, defaults or violations which, individually or in the aggregate, would

not reasonably be expected to have a Material Adverse Effect. Since December 31, 2017, neither

the   Company   nor   any   of   its   Subsidiaries   has   received   any   notification   with   respect   to   possible

conflicts, defaults or violations of applicable laws, except for notices relating to possible conflicts,

defaults or violations, which conflicts, defaults or   violations would not have a Material Adverse

Effect.

o)

Insurance .   The   Company   and   its   Subsidiaries   are   insured   by   insurers   of

recognized financial responsibility against such losses and risks and in such coverage, amounts

as   are   prudent   and   customary   in   the   businesses   in   which   the   Company   is   engaged,   including,

but not limited to, directors and officer s insurance coverage with coverage amounts that are at

least equal to the   aggregate Purchase   Price.    Neither the   Company nor   any Subsidiary has   any

6

SPA PRLX, T1, 2019-02-27



reason   to   believe   that   it   will   not   be   able   to   renew   its   existing   insurance   coverage   as   and   when

such coverage expires or   to obtain similar coverage   from similar insurers   as may be necessary

to continue its business without a significant increase in cost.

p)

No Shell . As of the date of this Agreement   the   Company is an   operating

company and, either (i) is not or has never been a shell issuer as defined in Rule 144(i)(2) or (ii)

at least 12 months have passed since the Company filed Form 10 Type information indicating it is

not   a   shell   issuer   (and   supporting   the   claim   that   it   is   no   longer   a   shell   company),      filed   all

required   reports   for   at   least   twelve   consecutive   months   after   the   filing   of   the   respective   Form   10

information, and has therefore complied with Rule 144(i)(2).

q)

Bad   Actor.   No   officer   or   director   of   the   Company   would   be   disqualified

under Rule 506(d) of the Securities Act as amended on the basis of being a bad actor .

r)

Acknowledgement

Regarding

Purchaser s

Trading

Activity .

Notwithstanding   anything   in   this   Agreement   or   elsewhere   to   the   contrary   it   is   understood   and

acknowledged by the Company that: (i) the Purchaser has not been asked by the Company to agree,

nor has   any Purchaser   agreed, to desist from purchasing or selling, securities of the   Company, or

derivative securities based on securities issued by the Company or to hold the Securities for any

specified term; (ii) each Purchaser shall not be deemed to have any affiliation with or control over

any arm s length counter-party in any derivative transaction.

s)     Sarbanes-Oxley Act. The Company and each Subsidiary is in material compliance with all

applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date

hereof,   and   all   applicable   rules   and   regulations   promulgated   by   the   SEC   thereunder   that

are effective as of the date hereof.

4.    COVENANTS.

a)

Best Efforts. The parties shall use their best efforts to satisfy timely each of

the conditions described in Section 6 and 7 of this Agreement.

b)

Form   D;   Blue   Sky   Laws.   The   Company   agrees   when   applicable   to   timely

file   a   Form   D   with   respect   to   the   Securities   as   required   under   Regulation   D   and   to   provide   a

copy thereof   to   the   Purchaser   promptly after   such   filing.   The   Company shall,   on   or   before   the

Closing   Date,   take   such   action   as   the   Company   shall   reasonably   determine   is   necessary   to

qualify  the  Securities  for  sale  to  the  Purchaser  at  the  applicable  closing  pursuant  to  this

Agreement under applicable securities or blue sky   laws of the states of the United States (or

to obtain an exemption from such qualification), and shall provide evidence of any such action

so taken to the Purchaser on or prior to the Closing Date.

c)

Use of Proceeds.   The Company shall use the proceeds   from the sale   of the

Securities for general corporate and administrative purposes.

7

SPA PRLX, T1, 2019-02-27



d)

Financial Information . Upon written request of the Purchaser, the Company

agrees   to   within   (3)   three   days   of   the   written   request   send   or   make   available   the   following

reports filed with the SEC or OTC Markets Group to the Purchaser: a copy of its Annual Report

and its Quarterly Reports and any Supplemental Reports; (ii) copies of all press releases issued

by the Company or   any of its Subsidiaries; and (iii) copies of any notices   or other information

the   Company   makes   available   or   gives   to   such   shareholders.   Notwithstanding   the   foregoing,

the Company shall not disclose any material nonpublic information to the Purchaser without its

consent   unless   such   information   is   disclosed   to   the   public   prior   to   or   promptly following such

disclosure to the Purchaser.

e)

Listing .   The   Company   will   obtain   and,   so   long   as   the   Purchaser   owns   any

of   the   Securities,   maintain   the   listing   and   trading   of   its   Common   Stock   on   the   OTCBB,   and

OTCQB, or any equivalent replacement exchange, the NASDAQ Stock Market ( NASDAQ ),

the New York Stock Exchange ( NYSE ), or the NYSE MKT, f/k/a American Stock Exchange

( AMEX ),   and   will   comply   in   all   respects   with   the   Company s   reporting,   filing   and   other

obligations under the bylaws or rules of the Financial Industry Regulatory Authority ( FINRA )

and   such   exchanges,   as   applicable.   The   Company   shall   promptly   provide   to   the   Purchaser

copies   of   any notices   it   receives   from   the   SEC,   OTC   Markets   Group   and   any other   exchanges

or   quotation   systems  on  which   the   Common   Stock   is  then   listed   regarding   the  continued

eligibility of the Common Stock for listing on such exchanges and quotation systems, provided

that it shall not provide any notices constituting material nonpublic information.   If at any time

while   the   Note   is   outstanding   the   Company   fails   to   maintain   the   listing   and   trading   and   of   its

Common Stock, or fails in any way to comply with the Company s reporting/ filing obligations

such   failure(s)   will   result   in   liquidated   damages   of   fifteen   thousand   dollars   ($15,000),   being

immediately due and   payable to Holder at its   election in the form of cash payment or   addition

to the balance of the Note.

f)

Corporate    Existence.    So    long  as    the  Purchaser    beneficially  owns    any

Securities,    the    Company  shall    maintain    its    corporate    existence    and    shall    not    sell    all    or

substantially   all   of   the   Company s   assets,   except   in   the   event   of   a   merger   or   consolidation   or

sale of all or substantially all of the Company s assets, where the surviving or successor entity

in such transaction (i) assumes the Company s obligations hereunder and under the agreements

and   instruments   entered   into   in   connection   herewith   and   (ii)   is   a   publicly   traded   corporation

whose Common Stock is listed for trading on NASDAQ, NYSE or AMEX.

g)

No   Integration.   The   Company   shall   not   make   any   offers   or   sales   of   any

security   (other   than   the   Securities)   under   circumstances   that   would   require   registration   of   the

Securities   being   offered   or   sold   hereunder   under   the   1933   Act   or   cause   the   offering   of   the

Securities to be integrated with any other offering of securities by the Company for the purpose

of any stockholder approval provision applicable to the Company or its securities.

h)

Securities   Laws   Disclosure;   Publicity .   The   Company   shall   comply   with

applicable   securities   laws   by filing   a   Current   Report   on   Form   8-K,   within   four   (4)   Trading   Days

following the date hereof, disclosing all the material terms of the transactions contemplated hereby.

i)

Non-Public   Information.     Except   with   respect   to   the   material   terms   and

conditions of the transactions contemplated by this Agreement, the Company covenants and agrees

8

SPA PRLX, T1, 2019-02-27



that neither it nor any other person   acting on its behalf will provide the Purchaser or its agents or

counsel    with    any    information    that    the    Company    believes    constitutes    material    non-public

information, unless prior thereto the Purchaser shall have executed a written agreement regarding

the   confidentiality and   use   of   such   information.   The   Company understands   and   confirms   that the

Purchaser   shall   be   relying on   the   foregoing covenant   in   effecting transactions   in   securities   of   the

Company.

j)

Subsidiaries.    So long as the Note remains   outstanding, the Company shall

not transfer any assets or rights to any of its subsidiaries or permit any of its subsidiaries to engage

in   any   significant   business   or   operations,   whether   such   subsidiaries   are   currently   existing   or

hereafter created.

k)

Insurance .    So   long   as   the   Note   remains   outstanding,   the   Company and   its

Subsidiaries shall maintain in full force and effect insurance reasonably believed by the Company

to be adequate coverage (a) on all assets and activities, covering property loss or damage and loss

of   income   by fire   or   other   hazards   or   casualty,   and   (b)   against   all   liabilities,   claims   and   risks   for

which it is customary for companies similarly situated to the Company to insure, including without

limitation applicable product liability insurance, required workmen s compensation insurance, and

other   insurance   covering   injury   or   damage   to   persons   or   property,   but   excluding   directors   and

officers  insurance   coverage.     The   Company   shall  promptly   furnish   or  cause   to   be  furnished

evidence of such insurance to the Purchaser, in form and substance reasonably satisfactory to the

Purchaser

l)

ROFR.  At any time while the Note is outstanding, the Company desires to

borrow   funds,   raise   additional   capital   and/or   issue   additional   promissory   notes   convertible   into

shares of securities of the Company (a Prospective Financing ), the Purchaser shall have the right

of first refusal to participate in the Prospective Financing, and the Company shall provide written

notice containing the terms of such   Prospective   Financing (the   ROFR Notice ) to   the Purchaser

prior to effectuating any such transaction .  The ROFR Notice shall specify all of the key terms of

the   Prospective   Financing,   including,   but   not   limited   to,   the   proposed   investment   amount,   the

proposed rate of interest, the proposed conversion price, the proposed term of the investment, the

type   and   number   of   securities   to   be   sold   and   any and   all   other   relevant   terms,   each   as   applicable.

Upon  Purchaser s  receipt  of  the  ROFR  Notice,  Purchaser  shall  have  the  exclusive  right  to

participate   in   such   Prospective   Financing(s),   upon   the   terms   specified   in   the   ROFR   Notice,   by

sending written notice to the Company within seven (7) business days after Purchaser s receipt of

the ROFR Notice.    In the   event Purchaser fails to   exercise its right of   first   refusal   with respect to

an   ROFR   Notice   within   the   time   set   forth   above,   Purchaser   shall   be   deemed   to   have   waived   its

right   of   first   refusal   with   respect   to   such   Prospective   Financing,   provided   that   it   shall   retain   such

right  with  respect  to   any   future   Prospective   Financing.     Notwithstanding   anything   contained

herein,  the  Company  shall  not  furnish  any  material  non-public  information  concerning  the

Company   without   the   Purchaser s   prior   written   consent,   and   shall   initially   only   indicate   to   the

Purchaser  that  the  Company   contemplates  a  financing.    Notwithstanding  anything  contained

herein,   in   no   event   shall   the   Purchaser   be   entitled   to   purchase   any   securities   which   would   cause

the   sum   of   (1)   the   number   of   shares   of   Common   Stock   beneficially owned   by the   Purchaser   and

its   affiliates   (other   than   shares   of   Common   Stock   which   may   be   deemed   beneficially   owned

through   the   ownership   of   the   unconverted   portion   of   the   Note   or   the   unexercised   or   unconverted

9

SPA PRLX, T1, 2019-02-27



portion   of   any   other   security   of   the   Company   subject   to   a   limitation   on   conversion   or   exercise

analogous to the limitations contained herein) and (2) the number of shares of directly or indirectly

purchasable   under   this   Section,   to   exceed   4.9%   of   the   outstanding   shares   of   Common   Stock   ( or

9.99%    of    the    total    issued    Common    Stock    of    the    Company  if    specified    by  Purchaser    and

accompanied with applicable documentation such as any Amendment made to this Agreement or

the Note).

m)

Future   Financings:   Except   for   sales   or   issuances   to   Company   employees,

and   members   of   the   Company s   board   of   directors,   from   the   date   hereof   until   such   time   as   the

Purchaser no longer holds any of the Securities, in the event the Company issues or sells any shares

of Common Stock or securities directly or indirectly convertible into or exercisable   for   Common

Stock ( Common Stock Equivalents ) or amends the transaction documents relating to any sale or

issuance of Common Stock or Common Stock Equivalents, and the Purchaser reasonably believes

that   the   terms   and   conditions   thereunder   are   more   favorable   to   such   investors   as   the   terms   and

conditions granted under this Agreement, Note or any document provided by the Purchaser to the

Company relating to any sale or issuance of Common Stock (the Transaction Documents ), upon

notice    to    the    Company    by    such    Purchaser,    the    Transaction    Documents    shall    be    deemed

automatically   amended   so   as   to   give   the   Purchaser   the   benefit   of   such   more   favorable   terms   or

conditions.   Promptly   following   a   request   to   the   Company   the   Company   shall   provide   Purchaser

with   all   executed   transaction   documents   relating   to   any   such   sale   or   issue   of   Common   Stock   or

Common    Stock    Equivalents.    Company    shall   deliver    acknowledgment    of    such    automatic

amendment    to    the    Transaction    Documents    to    Purchaser    in    form    and    substance    reasonably

satisfactory    to    the    Purchaser    (the    Acknowledgment )    within    three    (3)    business    days    of

Company s   receipt   of   request   from   Purchaser   (the   Deadline ),   provided   that   Company s   failure

to timely provide the Acknowledgement shall not affect the automatic amendments contemplated

hereby.   If   the   Acknowledgement   is   not   delivered   by   the   Deadline,   Company   shall   pay   to   the

Purchaser   $1000.00   per   day in   cash,   for   each   day beyond   the   Deadline   that   the   Company fails   to

deliver   such   Acknowledgement   such   cash   amount   shall   be   paid   to   Holder   by   the   first   day   of   the

month following the month in which it has accrued or, at the option of the Holder, shall be added

to the principal amount of the Note, in which event interest shall accrue thereon in accordance with

the   terms   of   the   Note   and   such   additional   principal   amount   shall   be   convertible   into   Common

Stock in accordance with the terms of the Note.

n)

Piggyback  Registration  Rights .  Borrower  shall  include  on  the:  (i)  next

registration statement Borrower files with the SEC; or (ii) on the subsequent registration statement

if   such   registration   statement   is   withdrawn),   or,   (iii)    amend   a   registration   statement   previously

filed, but not effective as of the Issue Date all shares issuable upon conversion of the Note. Failure

to do so will result in liquidated damages of fifty percent (50%) of the outstanding principal amount

of   the   Note,   but   not less   than   twenty-five   thousand   dollars   ($25,000),   being   immediately due   and

payable to Holder at its election in the form of cash payment or addition to the balance of the Note.

o)

Subsequent   Financings.   N otwithstanding   anything   contained   herein,   if   at

any   time   while   this   Note   is   outstanding   the   Company   enters   into   any   capital   raising   transaction,

including   without   limitation   an   equity line   transaction,   a   loan   transaction   or   the   sale   of   shares   of

Common   Stock   or   securities   convertible   into   or   exercisable   or   exchangeable   for   Common   Stock,

whether  or  not  permitted  under  the  Transaction  Documents  ( Subsequent  Financing ),  then

10

SPA PRLX, T1, 2019-02-27



following   the   closing   of   each   such   Subsequent   Financing   the   Holder   in   its   sole   and   absolute

discretion   may   compel   the   Company   to   redeem   up   to   the   entire   outstanding   balance   of   the   Note

from   the   gross   proceeds   therefrom   ( Redemption   Amount ),   provided   however   (a)   if   the   Holder

is holding other convertible notes similar to this Note whether issued prior or after the   Issue Date

of this Note (collectively with this Note, the Notes ), the Redemption Amount may be applied to

redeem any or all of the Notes specified by the Holder, (b) the Holder shall be notified in writing

of the closing of   each such Subsequent Financing within one (1) day following such   closing, and

(c) the Holder may elect   not to exercise its right to such redemption in whole or in part, in which

case   the   Company   may   not   redeem   any   Notes   in   connection   with   such   Subsequent   Financing   to

the extent so rejected (for clarification, if the holder elects to reject any redemption in any instance,

such rejection shall not affect the Holder s redemption rights hereunder in the future). Further, in

the   event   that   the   Holder   demands   redemption   of   a   portion   or   the   full   balance   of   the   Note   within

the   first   six   (6)   months   from   Note s   Issue   Date,   such   Redemption   Amount   shall   subject   to   then

then   applicable   Prepayment   Factor,   as   defined   in   the   Note   shall   be   applied).   To   the   extent   the

Company is   obligated   to   redeem   any portion   of   the   Notes   pursuant   to   this   Section   but   fails   to   do

so, such default shall constitute an Event of Default under all the Notes.

p)

Additional Investment Right. Purchaser shall have the right at any time from

time to time, as of the date hereof, and until such date when the Note is no longer outstanding, to

in its sole and absolute discretion purchase an additional convertible promissory note, or additional

convertible promissory notes, from the Company for up to a principal amount equal to the amount

of   the   Note   purchased   hereunder   (each   a   Subsequent   Note   and   collectively   the   Subsequent

Notes )   on   the   same   terms   and   conditions   as   applicable   to   the   purchase   and   sale   of   the   Note

purchased   on   the   date   hereof   by   Purchaser,   and   in   substantially   the   same   form   and   substance   as

the Note issued pursuant to this Agreement, mutatis mutandis , (each a Subsequent Note Purchase

and collectively Subsequent Note Purchases ).  For Purchaser to exercise such Subsequent Note

Purchase right,  Purchaser shall deliver  written notice, to the Company (for clarity notice sent via

electronic mail shall satisfy such written notice requirement) electing to exercise such Subsequent

Note Purchase right, which notice shall specify the principal amount of the Additional Note to be

purchased   by such   Purchaser   ( Subsequent   Note   Amount )   and   the   date   on   which   such   purchase

and   sale   shall   occur   ( Subsequent   Note   Closing ),   which   Subsequent   Note   Closing   shall   occur

within five (5)   days following such notice   by such   Purchaser, or   such other   date mutually agreed

upon by the Purchaser and Company. The terms and conditions of any Subsequent Note Purchase

shall   be   identical   to the   terms   and   conditions   set   forth   in   this   Agreement   applicable   to   the   sale   of

the Note on the date hereof, including without limitation each Subsequent Note will be in the form

of the Note issued hereto, provided that the Maturity Date thereunder shall be on ninth (9

th ) month

from the Subsequent Note s issue date. Further, if a warrant to purchase Company s common stock

was   issued   pursuant   to   this   Agreement   then   Purchaser   shall   receive   a    warrant   in   the   form   as   the

same    form    and    substance    as    the    warrant    issued    pursuant    to    this    Agreement    ( Subsequent

Warrant ),   provided   that   the   Termination   Date   of   the   Additional   Warrant   shall   be   the   fifth   (5 th )

anniversary   from   the   issue   date   of   the   Subsequent   Warrant.   On   or   prior   to   any   Subsequent   Note

Closing(s), the Company and the Purchaser shall, upon Purchaser s request, execute and deliver a

new   securities   purchase   agreement   with   respect   to   the   Subsequent   Note   Purchase(s)   in   the   same

form and substance as this Agreement (each a Subsequent Purchase Agreement and collectively

Subsequent   Purchase   Agreements ),   mutatis   mutandis ,   and   all   the   representations,   warrants,

covenants,   indemnities   and   conditions   set   forth   herein   shall   be   included   and   incorporated   with

11

SPA PRLX, T1, 2019-02-27



respect   to   such   Note   Purchase,   mutatis   mutandis .   Purchaser   may   assign   its   Subsequent   Note

Purchase right hereunder to any affiliate of such Purchaser.

q)

Subsequent   Financings.   Notwithstanding   anything   contained   herein   if   at

any   time   while   this   Note   is   outstanding   the   Company   enters   into   any   capital   raising   transaction,

including   without   limitation   an   equity line   transaction,   a   loan   transaction   or   the   sale   of   shares   of

Common   Stock   or   securities   convertible   into   or   exercisable   or   exchangeable   for   Common   Stock,

whether   or   not   permitted   under   the   Transaction   Documents   ( Subsequent   Financing ),   no   more

than five (5) Trading Days   following the closing of each such Subsequent Financing  in Holder s

sole and absolute discretion at least 50% of the gross proceeds therefrom ( Redemption Amount )

shall be paid to the Holder to redeem a portion of the Note s balance, provided however (a) if the

Holder is holding other convertible notes   similar to this Note issued by the Company (collectively

with this Note, the Notes ), the Redemption Amount shall be applied to redeem the Note specified

by the   Holder,   (b)   the   Holder   shall   be   notified   in   writing   of   the   closing   of   each   such   Subsequent

Financing   within   one   (1)   day   following   such   closing,   and   (c)   the   Holder   may   elect   to   reject   any

such   redemption   in   whole   or   in   part,   in   which   case   the   Company   may   not   redeem   any   Notes   in

connection with such Subsequent Financing to the extent so rejected (for clarification, if the Holder

elects  to  reject  any   redemption  in  any   instance,  such  rejection  shall  not  affect  the  Holder s

redemption rights hereunder in the future). To the extent the Company is obligated to redeem any

portion   of   the   Notes   pursuant   to   this   Section   but   fails   to   do   so,   such   default   shall   constitute   an

Event of Default under all the Notes.

5.    Transfer Agent Instructions . Upon receipt of a duly executed Notice of Conversion,

the   Company   shall  issue   irrevocable   instructions  to  its  transfer   agent  to  issue   certificates,

registered   in   the   name   of   the   Purchaser   or   its   nominee,   for   the   Conversion   Shares   in   such

amounts   as   specified   from   time   to   time   by the   Purchaser   to   the   Company   upon   conversion   of

the   Note,   or   any   part   thereof,   in   accordance   with   the   terms   thereof   (the   Irrevocable   Transfer

Agent   Instructions ).   In   the   event   that   the   Company proposes   to   replace   its   transfer   agent,   the

Company   shall  provide,  prior  to  the  effective  date  of  such  replacement,  a  fully   executed

Irrevocable    Transfer    Agent    Instructions  in  a    form  as  initially  delivered  pursuant  to  this

Agreement and the Securities (including but not limited to the provision to irrevocably reserve

shares   of   Common   Stock   in   the   Reserved   Amount   (as   defined   in   the   Note))   signed   by   the

successor  transfer  agent  (to  the  Company)  and  the  Company.  Prior  to  registration  of  the

Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold

pursuant   to   Rule   144   without   any   restriction   as   to   the   number   of   Securities   as   of   a   particular

date   that   can   then   be   immediately   sold,   all   such   certificates   shall   bear   the   restrictive   legend

specified in Section 2(g) of this Agreement. The Company warrants that: (i) no instruction other

than the   Irrevocable Transfer Agent   Instructions referred to in this Section 5, and stop transfer

instructions   to   give   effect   to   hereof   (in   the   case   of   the   Conversion   Shares,   prior   to   registration

of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may

be   sold   pursuant   to   Rule   144   without   any   restriction   as   to   the   number   of   Securities   as   of   a

particular date that can then be immediately sold), will be given by the Company to its transfer

agent and that the Securities shall otherwise be freely transferable on the books and records of

the Company as and to the extent provided in this Agreement and the Note; (ii) it will not direct

its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in transferring

12

SPA PRLX, T1, 2019-02-27



(or   issuing)(electronically   or   in   certificated   form)   any   certificate   for   Conversion   Shares   to   be

issued   to   the   Purchaser   upon   conversion   of   or   otherwise   pursuant   to   the   Note   as   and   when

required by the Note and this Agreement; and (iii) it will not fail to remove (or direct its transfer

agent   not   to   remove   or   impair,   delay,   and/or   hinder   its   transfer   agent   from   removing)   any

restrictive   legend   (or   to   withdraw   any   stop   transfer   instructions   in   respect   thereof)   on   any

certificate   for   any Conversion   Shares   issued   to   the Purchaser   upon   conversion   of   or   otherwise

pursuant   to   the   Note   as   and   when   required   by   the   Note   and   this   Agreement.   Nothing   in   this

Section   shall   affect   in   any   way the   Purchaser s   obligations   and   agreement   set   forth   in   Section

2(g) hereof to comply with all applicable prospectus delivery requirements, if any, upon re-sale

of the Securities. If the Purchaser provides the Company with (i) an opinion of counsel in form,

substance   and   scope   customary   for   opinions   in   comparable   transactions,   to   the   effect   that   a

public sale or transfer of such Securities may be made without registration under the 1933 Act

and such sale or transfer is effected or (ii) the Purchaser provides reasonable assurances that the

Securities can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in the

case  of  the  Conversion  Shares,  promptly  instruct  its  transfer  agent  to  issue  one  or  more

certificates,   free   from   restrictive   legend,   in   such   name   and   in   such   denominations   as   specified

by the Purchaser.   The   Company acknowledges   that   a   breach   by it   of   its   obligations   hereunder

will  cause  irreparable  harm  to  the  Purchaser,  by  vitiating  the  intent  and  purpose  of  the

transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at

law   for   a   breach   of   its   obligations   under   this   Section   5   may   be   inadequate   and   agrees,   in   the

event   of   a   breach   or   threatened   breach   by the   Company   of   the   provisions   of   this   Section,   that

the   Purchaser   shall   be   entitled,   in   addition   to   all   other   available   remedies,   to   an   injunction

restraining   any   breach   and   requiring   immediate   transfer,   without   the   necessity   of   showing

economic loss and without any bond or other security being required.

6.    Injunction Posting   of   Bond.  In   the   event   the   Purchaser   shall   elect   to   convert   the

Note   or   any   parts   thereof,   the   Company   may   not   refuse   conversion   or   exercise   based   on   any

claim that Purchaser or anyone associated or affiliated with Purchaser has been engaged in any

violation of law, or for any other reason.   In connection with any injunction sought or attempted

by the   Company,   the   Company shall   be   required   to   post   a   bond   at   least   equal   to   the   greater   of

either:  (i)   the  outstanding   principal  amount  of  the   Note;  and  (ii)   the  market  value  of   the

Conversion Shares sought to be converted, exercised or issued, based on the sale price per share

of Common Stock on the principal market on which it is traded.

7.    Delivery of Unlegended Shares.

a)

Within    three    (3)    business    days    (such    third    business    day    being    the

Unlegended   Shares   Delivery   Date )   after   the   business   day   on   which   the   Company   has

received (i) a notice that Conversion Shares, or any other Common Stock held by the Purchaser

has   been   sold   pursuant   to   a   registration   statement   or   Rule   144   under   the   1933   Act,   (ii)   a

representation   that   the   prospectus   delivery   requirements,   or   the   requirements   of   Rule   144,   as

applicable   and   if   required,   have   been   satisfied,   (iii)   the   original   share   certificates   representing

the shares of Common Stock that have been sold,   and (iv) in the case of sales under Rule 144,

customary representation letters of the Purchaser and, if required, Purchaser s broker regarding

compliance   with   the   requirements   of   Rule   144,   the   Company   at   its   expense,   (y)   shall   deliver,

and   shall   cause   legal   counsel   selected   by   the   Purchaser   to   deliver   to   its   transfer   agent   (with

copies   to   Purchaser)   an   appropriate   instruction   and   opinion   of   such   counsel,   directing   the

13

SPA PRLX, T1, 2019-02-27



delivery   of   shares   of   Common   Stock   without   any   legends   including   the   legend   set   forth   in

Section    4(h)    above    (the    Unlegended    Shares );    and    (z)    cause    the    transmission    of    the

certificates   representing   the   Unlegended   Shares   together   with   a   legended   certificate

representing the balance of the submitted Common Stock certificate, if any, to the Purchaser at

the address specified in the notice of sale, via express courier, by electronic transfer or otherwise

on or before the Unlegended Shares Delivery Date.

b)

The   Company   understands   that   a   delay   in   the   delivery   of   the   Unlegended

Shares   later   than   the   Unlegended   Shares   Delivery   Date   could   result   in   economic   loss   to   the

Purchaser.     As   compensation   to   Purchaser   for   such   loss,   the   Company   agrees   to   pay   late

payment fees (as liquidated damages and not as a   penalty) to the Purchaser for late delivery of

Unlegended   Shares   in   the   amount   of   $250.00   per   business   day   after   the   Unlegended   Shares

Delivery   Date.   If   during   any   three   hundred   and   sixty   (360)   day   period,   the   Company   fails   to

deliver Unlegended Shares as required by this Section for an aggregate of thirty (30) days, then

Purchaser   or   assignee   holding   Securities   subject   to   such   default   may,   at   its   option,   require   the

Company to redeem all or any portion of the shares subject to such default at a price per share

equal   to   the   greater   of   (i)   200%   of   the   most   recent   closing   price   of   the   Common   Stock   or   (ii)

the  parity   value  of  the  Default  Sum  to  be  paid  (as  defined  in  Section  3.16  of  the  Note)

( Unlegended Redemption Amount ).  The Company shall pay any payments incurred under

this Section in immediately available funds upon demand.

8.    Conditions   to   the   Company s   Obligation   to   Sell.   The   obligation   of   the   Company

hereunder to issue and sell the Note to the Purchaser at the Closing is subject to the satisfaction,

at or before the Closing Date of each of the following conditions provided that these conditions

are   for the Company s   sole benefit   and may be   waived by the Company at   any time in its sole

discretion:

a)

The   Purchaser   shall   have   executed   this   Agreement   and   delivered   the   same

to the Company.

b)

The Purchaser shall have delivered the Purchase Price to the Company.

c)

The representations and warranties of the Purchaser shall be true and correct

in all material respects as   of the date when made and as of the Closing Date as though made at

that   time   (except   for   representations   and   warranties   that   speak   as   of   a   specific   date),   and   the

Purchaser  shall  have  performed,  satisfied  and  complied  in  all  material  respects  with  the

covenants, agreements and conditions required by this Agreement to be performed, satisfied or

complied with by the Purchaser at or prior to the Closing Date.

d)

No   litigation,   statute,   rule,   regulation,   executive   order,   decree,   ruling   or

injunction   shall   have   been   enacted,   entered,   promulgated   or   endorsed   by   or   in   any   court   or

governmental   authority   of   competent   jurisdiction   or   any   self-regulatory   organization   having

authority over the matters contemplated hereby which prohibits the consummation of any of the

transactions contemplated by this Agreement.

9.    Conditions  to  The  Purchaser s  Obligation  to  Purchase .  The  obligation  of  the

Purchaser   hereunder   to   purchase   the   Note   at   the   Closing   is   subject   to   the   satisfaction,   at   or

14

SPA PRLX, T1, 2019-02-27



before the Closing Date of each of the following conditions, provided that these conditions are

for   the   Purchaser s   sole   benefit   and   may   be   waived   by   the   Purchaser   at   any   time   in   its   sole

discretion:

a)

The   Company shall   have   executed   this   Agreement   and   delivered   the   same

to the Purchaser.

b)

The Company shall have delivered to the Purchaser the duly executed Note

(in such denominations as the Purchaser shall request) in accordance with Section 1 above.

c)

The    Irrevocable    Transfer    Agent    Instructions,    in    form    and    substance

satisfactory to the Purchaser, shall have been delivered to and   acknowledged in writing by the

Company s   Transfer   Agent   (a   copy   of   which   written   acknowledgment   shall   be   provided   to

Purchaser prior to Closing).

d)

The representations and warranties of the Company shall be true and correct

in all material respects as of the date when made and as of the Closing Date as though made at

such   time   (except   for   representations   and   warranties   that   speak   as   of   a   specific   date)   and   the

Company  shall  have  performed,  satisfied  and  complied  in  all  material  respects  with  the

covenants, agreements and conditions required by this Agreement to be performed, satisfied or

complied   with   by   the   Company   at   or   prior   to   the   Closing   Date.   The   Purchaser   shall   have

received   a   certificate   or   certificates   reasonably   requested   by   the   Purchaser   including,   but   not

limited   to   certificates   with   respect   to   the   Company s   Formation   Documents,   By-laws,     and

Board of Directors resolutions relating to the transactions contemplated hereby.

e)

No   litigation,   statute,   rule,   regulation,   executive   order,   decree,   ruling   or

injunction   shall   have   been   enacted,   entered,   promulgated   or   endorsed   by   or   in   any   court   or

governmental   authority   of   competent   jurisdiction   or   any   self-regulatory   organization   having

authority over the matters contemplated hereby which prohibits the consummation of any of the

transactions contemplated by this Agreement.

f)

No   event   shall   have   occurred   which   could   reasonably be   expected   to   have

a   Material   Adverse   Effect   on   the   Company   including   but   not   limited   to   a   change   in   the   1934

Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act

reporting obligations.

g)

The   Conversion   Shares   shall   have   been   authorized   for   quotation   on   the

OTCBB, OTCQB, and OTC Pink and trading of the Common Stock on the OTCBB, OTCQB,

and OTC Pink shall not have been suspended by the SEC or the OTC Markets Group.

10. Governing Law; Miscellaneous.

a)

Governing   Law .   This   Agreement   shall   be   governed   by   and   construed   in

accordance with the laws of the State of Nevada without regard to principles of conflicts of laws

thereof   or   any   other   State.  Any   action   brought   by   any   party   against   any   other   party   hereto

concerning the   transactions   contemplated   by this   Agreement   shall   be   brought   only in   the   state

courts of New   York or in   the federal courts located in the state   and county of New   York.  The

parties   to   this   Agreement   hereby irrevocably waive   any objection   to   jurisdiction   and   venue   of

15

SPA PRLX, T1, 2019-02-27



any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or

venue or based upon forum non conveniens.  The parties executing this Agreement and other

agreements  referred  to  herein  or  delivered  in  connection  herewith  on  behalf  of  the

Company   agree   to   submit   to   the   in   personam   jurisdiction   of   such   courts   and   hereby

irrevocably   waive   trial   by   jury.  The   prevailing   party   shall   be   entitled   to   recover   from   the

other   party   its   reasonable   attorney s   fees   and   costs.  In   the   event   that   any   provision   of   this

Agreement or any other agreement delivered in connection herewith is invalid or unenforceable

under any applicable statute or rule of law, then such provision shall be deemed inoperative to

the   extent   that   it   may   conflict   therewith   and   shall   be   deemed   modified   to   conform   with   such

statute or rule of law.  Any such provision which may prove invalid or unenforceable under any

law shall not affect the validity or enforceability of any other provision of any agreement.  Each

party   hereto   hereby   irrevocably   waives   personal   service   of   process   and   consents   to   process

being served   in   any suit,   action   or   proceeding in   connection   with   this   Agreement   or   any other

transaction document contemplated hereby by mailing a copy thereof via registered or certified

mail or overnight delivery (with evidence of delivery) to such party at the address in effect for

notices   to   it   under   this   Agreement  and   agrees   that   such   service   shall   constitute   good   and

sufficient   service   of   process   and   notice   thereof.  Nothing   contained   herein   shall   be   deemed   to

limit in any way any right to serve process in any other manner permitted by law.

b)

Removal of Restrictive Legends.  In the event that Purchaser has any shares

of   the   Company s   Common   Stock   bearing   any   restrictive   legends,   and   Purchaser,   through   its

counsel or other representatives, submits to the Transfer Agent any such shares for the removal

of    the    restrictive    legends    thereon    in    connection    with    a    sale    of    such    shares    pursuant

to any exemption   to   the   registration   requirements   under   the   Securities   Act,   and   the   Company

and or its counsel refuses or fails for any reason (except to the extent that such refusal or failure

is based solely on applicable law that would prevent the removal of such restrictive legends) to

render an opinion of counsel or any other documents or certificates required for the removal of

the   restrictive   legends,   then   the   Company hereby   agrees   and   acknowledges   that   the   Purchaser

is hereby irrevocably and expressly authorized to have counsel to the Purchaser render any and

all  opinions  and  other  certificates  or  instruments  which  may   be  required  for  purposes  of

removing such restrictive legends, and the Company hereby irrevocably authorizes and directs

the Transfer Agent to, without any further confirmation or instructions from the Company, issue

any   such   shares   without   restrictive   legends   as   instructed   by   the   Purchaser,   and   surrender   to   a

common carrier for overnight delivery to the address as specified by the Purchaser, certificates,

registered   in   the   name   of   the   Purchaser   or   its   designees,   representing   the   shares   of   Common

Stock   to   which   the   Purchaser   is   entitled,   without   any   restrictive   legends   and   otherwise   freely

transferable on the books and records of the Company.

c)

Filing   Requirements .    From   the   date   of   this   Agreement   until   the   Notes   are

no   longer   outstanding,   the   Company   will   timely   and   voluntarily   comply   with   all   reporting

requirements that are applicable to an issuer with a class of shares registered pursuant to Section

12(g)    of    the    1934    Act,    whether    or    not    the    Company  is    then    subject    to    such    reporting

requirements,   and   comply   with   all   requirements  related   to   any   registration   statement   filed

pursuant to this Agreement.  The Company will use reasonable efforts not to take any action or

file   any   document   (whether   or   not   permitted   by   the   1933   Act   or   the   1934   Act   or   the   rules

thereunder)   to   terminate   or   suspend   such   registration   or   to   terminate   or   suspend   its   reporting

and   filing obligations   under   said   acts   until   the Notes   are   no   longer   outstanding.   The   Company

16

SPA PRLX, T1, 2019-02-27



will maintain the quotation or listing of its Common Stock on the OTCBB, OTCQB, NYSE, or

NASDAQ  Stock  Market  (whichever  of  the  foregoing  is  at  the  time  the  principal  trading

exchange   or   market   for   the   Common   Stock   (the   Principal   Market ),   and   will   comply in   all

respects   with   the   Company s   reporting,   filing   and   other   obligations   under   the   bylaws   or   rules

of the Principal Market, as applicable. The Company will provide Purchaser with copies of all

notices it receives notifying the Company of the threatened and actual delisting of the Common

Stock   from   any Principal   Market.  As   of   the   date   of   this   Agreement   and   the   Closing   Date,   the

OTCQB,   is   the   Principal   Market.   Until   the   Note   is   no   longer   outstanding,   the   Company   will

continue the listing or quotation of the Common Stock on a   Principal Market and   will comply

in   all   respects   with   the   Company s   reporting,   filing   and   other   obligations   under   the   bylaws   or

rules of the Principal Market.

d)

Fees   and   Expenses.    On   or   prior   to   the   Closing,   the   Company shall   pay or

reimburse   to   Purchaser   a   non-refundable,   non-accountable   sum   equal   to   $4,440.00   as   and   for

the fees, costs and expenses (including without limitation legal fees and disbursements and due

diligence  and  administrative  expenses)  incurred  by  the  Purchaser  in  connection  with  the

Purchaser s  due    diligence    and  negotiation,  preparation    and  execution    of  the    Transaction

Documents and consummation of the Transactions.   The Purchaser may withhold and offset the

balance of such amount from the payment of its Purchase Price otherwise payable hereunder at

Closing, which offset shall constitute partial payment of such Purchase Price in an amount equal

to such offset.  Except as expressly set forth in this Agreement or the Note to the contrary, each

party shall pay the   fees   and expenses of its advisers, counsel, accountants and other experts, if

any,   and   all   other   expenses   incurred   by   such   party   incident   to   the   negotiation,   preparation,

execution,   delivery   and   performance   of   this   Agreement.   The   Company   shall   pay   all   transfer

agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any

Securities to the Purchaser.

e)

Usury .   To the extent it may lawfully do so, the Company hereby agrees not

to insist upon or plead or in any manner whatsoever claim, and will resist any and all efforts to

be   compelled   to   take   the   benefit   or   advantage   of,   usury laws   wherever   enacted,   now   or   at   any

time hereafter in force, in connection with any claim, action or proceeding that may be brought

by the Purchaser in order to enforce any right or remedy under the Note.  Notwithstanding any

provision   to   the   contrary   contained   in   herein   or   under   the   Note,   it   is   expressly   agreed   and

provided   that   the   total   liability   of   the   Company   under   the   Note   for   payments   in   the   nature   of

interest  shall  not  exceed  the  maximum  lawful  rate  authorized  under  applicable  law  (the

Maximum Rate ), and, without limiting the foregoing, in no event shall any rate of interest or

default interest, or both of them, when aggregated with any other sums in the nature of interest

that   the   Company   may   be   obligated   to   pay   under   the   Note   or   herein   exceed   such   Maximum

Rate.    It   is   agreed   that   if   the   maximum   contract   rate   of   interest   allowed   by law   and   applicable

to the Note is increased or decreased by statute or any official governmental action subsequent

to   the   date   hereof,   the   new   maximum   contract   rate   of   interest   allowed   by   law   will   be   the

Maximum Rate applicable to the Note from the effective date forward, unless such application

is   precluded   by   applicable   law.    If   under   any   circumstances   whatsoever,   interest   in   excess   of

the   Maximum   Rate   is   paid   by   the   Company   to   the   Purchaser   with   respect   to   indebtedness

evidenced   by   the   Note,   such   excess   shall   be   applied   by   the   Purchaser   to   the   unpaid   principal

balance of any such indebtedness or be refunded to the Company, the manner of handling such

excess to be at the Purchaser s election.

17

SPA PRLX, T1, 2019-02-27



f)

Headings. The headings of this Agreement are for convenience of reference

only and shall not form part of, or affect the interpretation of, this Agreement.

g)

Severability . In the event that any provision of this Agreement is invalid or

unenforceable under any applicable statute or rule of law, then such provision shall be deemed

inoperative to the extent that it may conflict therewith and shall be deemed modified to conform

with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable

under any law shall not affect the validity or enforceability of any other provision hereof.

h)

Entire    Agreement;    Amendments .    This    Agreement    and    the    instruments

referenced   herein   contain   the   entire   understanding   of   the   parties   with   respect   to   the   matters

covered   herein   and   therein   and,   except   as   specifically   set   forth   herein   or   therein,   neither   the

Company nor the Purchaser makes any representation, warranty, covenant or undertaking with

respect to such matters. No provision of this Agreement may be waived or amended other than

by an instrument in writing signed by the Purchaser.

i)

Notices.  All  notices,  demands,  requests,  consents,  approvals,  and  other

communications   required   or   permitted   hereunder   shall   be   in   writing   and,   unless   otherwise

specified herein, shall be: (i) personally served, (ii) deposited in the mail, registered or certified,

return   receipt   requested,   postage   prepaid,   (iii)   delivered   by   reputable   air   courier   service   with

charges   prepaid,   or   (iv)   transmitted   by   hand   delivery,   telegram,   email   or   facsimile,   addressed

as   set   forth   below   or   to   such   other   address   as   such   party shall   have   specified   most   recently by

written notice. Any notice or other communication required or permitted to be given hereunder

shall be deemed effective (a) upon hand delivery or delivery by email or facsimile with accurate

confirmation generated by the transmitting facsimile machine or computer, at the address, email

address   or   facsimile   number   designated   below   (if   delivered   on   a   business   day   during   normal

business   hours   where   such   notice   is   to   be   received),   or   the   first   business   day   following   such

delivery   (if   delivered   other   than   on   a   business   day   during   normal   business   hours   where   such

notice   is   to   be   received)   or   (b)   on   the   second   business   day   following   the   date   of   mailing   by

express courier service, fully prepaid, addressed to such address, or upon actual receipt of such

mailing, whichever shall first occur. The addresses for such communications shall be:

Purchaser:

EMA Financial, LLC

40 Wall Street, 17 th Floor

New York, NY 10005

Attn: Jamie Beitler

jbeitler@emafin.com

Company:

Parallax Health Sciences, Inc.

1327 Ocean Ave, Suite B

Santa Monica, CA 90401

Attn: Paul R. Arena, CEO

Email: ________________

Fax: ________________

Each party shall provide notice to the other party of any change in address.

18

SPA PRLX, T1, 2019-02-27



j)

Successors   and   Assigns.   This   Agreement   shall   be   binding   upon   and   inure

to   the   benefit   of   the   parties   and   their   successors   and   assigns.   Neither   the   Company   nor   the

Purchaser   shall   assign   this   Agreement   or   any rights   or   obligations   hereunder   without   the   prior

written  consent  of  the  other.  Notwithstanding  the  foregoing,  subject  to  Section  2(f),  the

Purchaser   may   assign   its   rights   hereunder   to   any   person   that   purchases   Securities   in   a   private

transaction from the Purchaser or to any of its affiliates, as that term is defined under the 1934

Act, without the consent of the Company.

k)

Third Party Beneficiaries. This Agreement is intended for the benefit of the

parties   hereto   and   their   respective   permitted   successors   and   assigns,   and   is   not   for   the   benefit

of, nor may any provision hereof be enforced by, any other person.

l)

Survival.  The  representations  and  warranties  of  the  Company  and  the

agreements   and   covenants   set   forth   in   this   Agreement   shall   survive   the   Closing   hereunder

notwithstanding   any   due   diligence   investigation   conducted   by   or   on   behalf   of   the   Purchaser.

The   Company   agrees   to   indemnify   and   hold   harmless   the   Purchaser   and   all   their   officers,

directors, employees and agents for loss or damage arising as a result of or related to any breach

or   alleged   breach   by   the   Purchaser   of   any   of   its   representations,   warranties   and   covenants   set

forth in this Agreement or any of its covenants and obligations under this Agreement, including

advancement of expenses as they are incurred.

m)

Further   Assurances.   Each   party   shall   do   and   perform,   or   cause   to   be   done

and   performed,   all   such   further   acts   and   things,   and   shall   execute   and   deliver   all   such   other

agreements, certificates, instruments and documents, as the other party may reasonably request

in  order  to  carry  out  the  intent  and  accomplish  the  purposes  of  this  Agreement  and  the

consummation of the transactions contemplated hereby.

n)

No  Strict  Construction .  The  language  used  in  this  Agreement  will  be

deemed to be the language chosen by the parties to express their mutual intent, and no rules of

strict construction will be applied against any party.

o)

Remedies. The Company acknowledges that a breach by it of its obligations

hereunder will cause irreparable harm to the Purchaser by vitiating the intent and purpose of the

transaction contemplated   hereby. Accordingly, the Company acknowledges that the remedy at

law   for   a   breach   of   its   obligations   under   this   Agreement   will   be   inadequate   and   agrees,   in   the

event   of   a   breach   or   threatened   breach   by   the   Company   of   the   provisions   of   this   Agreement,

that the Purchaser shall be entitled, in addition to all other available remedies at law or in equity,

and   in   addition   to   the   penalties   assessable   herein,   to   an   injunction   or   injunctions   restraining,

preventing   or   curing   any   breach   of   this   Agreement   and   to   enforce   specifically   the   terms   and

provisions   hereof,   without   the   necessity   of   showing   economic   loss   and   without   any   bond   or

other security being required.

p)

Counterparts.     This    Agreement    may    be    executed    in    any    number    of

counterparts, each of   which when so   executed   and   delivered   shall be deemed to be   an original

and   all   of   which   together   shall   be   deemed   to   be   one   and   the   same   agreement.   Any   signature

19

SPA PRLX, T1, 2019-02-27



transmitted   by   facsimile,   e-mail,   or   other   electronic   means   shall   be   deemed   to   be   an   original

signature.

[Remainder of Page Intentionally Left Blank]

20

SPA PRLX, T1, 2019-02-27



IN    WITNESS    WHEREOF,    the    undersigned    Purchaser    and    the    Company  have    caused    this

Agreement to be duly executed as of the date first above written.

PARALLAX HEALTH SCIENCES, INC.

By:

Name: Paul R. Arena

Title: CEO

EMA FINANCIAL, LLC

By:

Name:   Jamie Beitler

Title:     Authorized Signatory

GUARANTY

Each    of    the    undersigned    subsidiaries    of    the    Company    jointly    and    severally,    absolutely,

unconditionally   and   irrevocably,   guarantees  to   the   Purchaser   and   their  respective   successors,

indorsees,   transferees   and   assigns,   the   prompt   and   complete   payment   and   performance   by   the

Company when   due   (whether   at   the   stated   maturity,   by acceleration   or   otherwise)   of   all   amounts

due   under,   and   all   other   obligations   under,   the   Note.    Each   such   subsidiary s   liability   under   this

Guaranty shall be unlimited, open and continuous for so long as this Guaranty remains in force.

PARALLAX   HEALTH  MANAGEMENT,      PARALLAX COMMUNICATIONS,

INC.

INC.

By:

By:

Print Name:

Print Name:

Title:

Title:

PARALLAX BEHAVIORAL HEALTH, INC.     PARALAX DIAGNOSTICS, INC.

By:

By:

Print Name:

Print Name:

Title:

Title:

ROXSAN PHARMACY, INC

By:

Print Name:

Title:

21

SPA PRLX, T1, 2019-02-27



NEITHER    THIS    SECURITY    NOR    THE    SECURITIES    FOR    WHICH    THIS    SECURITY    IS

EXERCISABLE    HAVE    BEEN    REGISTERED    WITH    THE    SECURITIES    AND    EXCHANGE

COMMISSION  OR  THE  SECURITIES  COMMISSION  OF  ANY  STATE  IN  RELIANCE  UPON  AN

EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE

SECURITIES   ACT ),   AND,   ACCORDINGLY,   MAY   NOT   BE   OFFERED   OR   SOLD   EXCEPT

PURSUANT   TO   AN   EFFECTIVE   REGISTRATION   STATEMENT   UNDER   THE   SECURITIES   ACT   OR

PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,

THE   REGISTRATION   REQUIREMENTS   OF   THE   SECURITIES   ACT   AND   IN   ACCORDANCE   WITH

APPLICABLE   STATE   SECURITIES   LAWS.     THIS   SECURITY   AND   THE   SECURITIES   ISSUABLE

UPON   EXERCISE   OF   THIS   SECURITY   MAY   BE   PLEDGED   IN   CONNECTION   WITH   A   BONA   FIDE

MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

COMMON STOCK PURCHASE WARRANT

PARALLAX HEALTH SCIENCES, INC.

Warrant Shares: 300,000

Issue   Date:   February   27,   2019

THIS   COMMON   STOCK   PURCHASE   WARRANT   (the   Warrant )   certifies   that,   for   value

received,   EMA   Financial,   LLC,   a   Delaware   limited   liability   company   (the   Holder ),   is   entitled,   upon   the

terms   and   subject   to   the   limitations   on   exercise   and   the   conditions   hereinafter   set   forth,   at   any   time   on   or

after the Issue Date (as defined above) and on or prior to the close of business on the fifth (5 th ) anniversary of

the   Issue   Date   (the   Expiration   Date )   but   not   thereafter,   to   subscribe   for   and   purchase   from   PARALLAX

HEALTH   SCIENCES,   INC.,   a   Nevada   corporation   (the   Company ),   up   to   300,000   shares   (the   Warrant

Shares )   (whereby   such   number   may   be   adjusted   from   time   to   time   pursuant   to   the   terms   and   conditions   of   this

Warrant)   of   Common   Stock.    The   purchase   price   of   one   share   of   Common   Stock   under   this   Warrant   shall   be

equal   to   the   Exercise   Price,   as   defined   in   Section   2(b),   subject   to   adjustment   herein.    This   Warrant   is   issued

by   the   Company   as   of   the   date   hereof   in   connection   with   that   certain   securities   purchase   agreement   dated

February 27, 2019 by and among the Company and the Holder.

Section 1.

Definitions .   Capitalized   terms   used   and   not   otherwise   defined   herein   shall   have   the

meanings   set   forth   in   that   certain   Securities   Purchase   Agreement   (the   Purchase   Agreement ),   dated   on   or

about   the   date   hereof,   among   the   Company   and   the   Holder,   among   others,   pursuant   to   which   this   Warrant   is

being issued.

Section 2.

Exercise.

a)

Exercise   of   Warrant.    Exercise   of   the   purchase   rights   represented   by this   Warrant   may

be   made,   in   whole   or   in   part,   at   any   time   and   from   time   to   time   on   or   after   the   Issue   Date   and   on   or

before the Expiration

b)

Date by delivery to the Company (or such other   office or   agency of the Company as it

may designate   by notice   in   writing to   the   registered   Holder   at   the   address   of the   Holder   appearing on

the  books  of  the  Company)  of  a  duly  executed  facsimile  copy  of  the  Notice  of  Exercise  Form

annexed   hereto   ( Notice   of   Exercise )   (which   delivery   may   be   made   in   any   manner   set   forth   in   the

Purchase   Agreement,   including   without   limitation   by   email);   and,   within   three   (3)   Trading   Days   of

the   date   said   Notice   of   Exercise   is   delivered   to   the   Company,   the   Company   shall   have   received

payment of the   aggregate   Exercise Price   of the   shares thereby purchased by wire transfer or   cashier s

check drawn on a United   States   bank, unless payment is being made by cashless exercise as provided

1

Warrant PRLX, T1, 2019-02-27



in   Section   2(c)   below.     Notwithstanding   anything   herein   to   the   contrary,   the   Holder   shall   not   be

required   to   physically   surrender   this   Warrant   to   the   Company   until   the   Holder   has   purchased   all   of

the   Warrant   Shares   available   hereunder   and   the   Warrant   has   been   exercised   in   full,   in   which   case   the

Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of

the   date   the   final   Notice   of   Exercise   is   delivered   to   the   Company.    Partial   exercises   of   this   Warrant

resulting   in   purchases   of   a   portion   of   the   total   number   of   Warrant   Shares   available   hereunder   shall

have   the   effect   of   lowering   the   outstanding   number   of   Warrant   Shares   purchasable   hereunder   in   an

amount   equal   to   the   applicable   number   of   Warrant   Shares   purchased.    The   Holder   and   the   Company

shall  maintain  records  showing  the  number  of  Warrant  Shares  purchased  and  the  date  of  such

purchases.  The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,

by   reason   of   the   provisions   of   this   paragraph,   following   the   purchase   of   a   portion   of   the   Warrant

Shares   hereunder,   the   number   of   Warrant   Shares   available   for   purchase   hereunder   at   any   given   time

may be less than the amount stated on the face hereof.

c)

Exercise Price.    The   exercise price per share of the Common Stock under this Warrant

shall be $0.15 subject to adjustment hereunder (the Exercise Price ).

d)

Cashless  Exercise.      In  the  event  that  the  shares  underlying  this  Warrant  are  not

registered   for   resale   with   the   Securities   and   Exchange   Commission   under   an   effective   registration

statement with a current   prospectus, then this Warrant may also be exercised by means of   a cashless

exercise   in   which   the   Holder   shall   be   entitled   to   receive   a   certificate   for   the   number   of   Warrant

Shares equal to the quotient obtained by dividing [(A-B) (X)] by (B), where:

(A) =  the Market Price (as defined below);

(B) =  the Exercise Price of this Warrant (as adjusted); and

(X)   =   the   number   of   Warrant   Shares   issuable   upon   exercise   of   this   Warrant   in   accordance

with   the   terms  of   this  Warrant  by   means  of  a  cash   exercise   rather   than  a   cashless

exercise.

Market   Price   shall   mean   the   closing   sale   price   per   share   of   Common   Stock   on   the   principal

market where the Common Stock is traded on the Trading Day immediately preceding delivery of the

Notice   of   Exercise   or   the   Closing   Date,   whichever   is   greater.   Notwithstanding   anything   herein   to   the

contrary,   on   the   Expiration   Date,   this   Warrant   shall   be   automatically   exercised   via   cashless   exercise

pursuant to this Section 2(c).

e)

Holder s Restrictions .  The Company shall not effect any exercise of this Warrant, and

a   Holder   shall   not   have   the   right   to   exercise   any   portion   of   this   Warrant,   pursuant   to   Section   2   or

otherwise,   to   the   extent   that   after   giving   effect   to   such   issuance   after   exercise   as   set   forth   on   the

applicable Notice of Exercise, the Holder   (together with the Holder s Affiliates, and any other person

or  entity  acting  as  a  group  together  with  the  Holder  or  any  of  the  Holder s  Affiliates),  would

beneficially own   in   excess   of   the   Beneficial   Ownership   Limitation   (as   defined   below).    For   purposes

of   the   foregoing   sentence,   the   number   of   shares   of   Common   Stock   beneficially owned   by the   Holder

and   its   Affiliates   shall   include   the   number   of   shares   of   Common   Stock   issuable   upon   exercise   of   this

Warrant   with   respect   to   which   such   determination   is   being   made,   but   shall   exclude   the   number   of

shares   of   Common   Stock   which   would   be   issuable   upon   (A)   exercise   of   the   remaining,   nonexercised

portion   of   this   Warrant   beneficially   owned   by   the   Holder   or   any   of   its   Affiliates   and   (B)   exercise   or

conversion  of  the  unexercised  or  nonconverted  portion  of  any  other  securities  of  the  Company

(including,   without   limitation,   any   rights   or   securities   convertible   into   or   exercisable   for   Common

2

Warrant PRLX, T1, 2019-02-27



Stock   ( Common   Stock   Equivalents ))   subject   to   a   limitation   on   conversion   or   exercise   analogous   to

the   limitation   contained   herein   beneficially   owned   by   the   Holder   or   any   of   its   Affiliates.    Except   as

set   forth   in   the   preceding   sentence,   for   purposes   of   this   Section   2(d),   beneficial   ownership   shall   be

calculated  in  accordance  with  Section  13(d)  of  the  Exchange  Act  and  the  rules  and  regulations

promulgated   thereunder.    To   the   extent   that   the   limitation   contained   in   this   Section   2(d)   applies,   the

determination   of   whether   this   Warrant   is   exercisable   (in   relation   to   other   securities   owned   by   the

Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the

sole   discretion   of   the   Holder,   and   the   submission   of   a   Notice   of   Exercise   shall   be   deemed   to   be   the

Holder s   determination   of   whether   this   Warrant   is   exercisable   (in   relation   to   other   securities   owned

by   the   Holder   together   with   any   Affiliates)   and   of   which   portion   of   this   Warrant   is   exercisable,   in

each   case   subject   to   the   Beneficial   Ownership   Limitation,   and   the   Company shall   have   no   obligation

to verify or confirm the accuracy of such determination.     In addition, a determination as to any group

status   as   contemplated   above   shall   be   determined   in   accordance   with   Section   13(d)   of   the   Exchange

Act   and   the   rules   and   regulations   promulgated   thereunder.     For   purposes   of   this   Section   2(d),   in

determining the number of outstanding shares of Common Stock, a Holder may rely on the number of

outstanding   shares   of   Common   Stock   as   reflected   in   (x)   the   Company s   most   recent  periodic   or

annual report, as the case   may be, (y)   a more   recent public announcement   by the Company or (z) any

other   notice   by the   Company or   the   Company s   Transfer   Agent   setting   forth   the   number   of   shares   of

Common   Stock   outstanding.    Upon   the   written   or   oral   request   of   a   Holder,   the   Company shall   within

two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock

then    outstanding.     In    any    case,    the    number    of    outstanding    shares    of    Common    Stock    shall    be

determined   after   giving   effect   to   the   conversion   or   exercise   of   securities   of   the   Company,   including

this   Warrant,   by   the   Holder   or   its   Affiliates   since   the   date   as   of   which   such   number   of   outstanding

shares   of   Common   Stock   was   reported.    The   Beneficial   Ownership   Limitation shall   be   4.9%   of   the

number of shares of the Common Stock outstanding immediately after giving effect to the issuance of

shares   of   Common   Stock   issuable   upon   exercise   of   this   Warrant.    By written   notice   to   the   Company,

the   Holder   may   at   any   time   and   from   time   to   time   increase   or   decrease   the   Beneficial   Ownership

Limitation   to   any other   percentage   specified   in   such   notice   (or   specify that   the   Beneficial   Ownership

Limitation    shall    no    longer    be    applicable),    provided,    however,    that    (A)    any    such    increase    (or

inapplicability)   shall   not   be   effective   until   the   sixty-first   (61st)   day   after   such   notice   is   delivered   to

the   Company,   and   (B)   any   such   increase   or   decrease   shall   apply   only   to   the   Holder   and   not   to   any

other   holder   of   Warrants.   The   provisions   of   this   paragraph   shall   be   construed   and   implemented   in   a

manner  otherwise  than    in  strict  conformity  with  the  terms  of  this  Section  2(d)  to  correct  this

paragraph    (or    any    portion    hereof)    which    may    be    defective    or    inconsistent    with    the    intended

Beneficial   Ownership   Limitation   herein   contained   or   to   make   changes   or   supplements   necessary   or

desirable   to   properly   give   effect   to   such   limitation.   The   limitations   contained   in   this   paragraph   shall

apply to a successor holder of this Warrant.

f)

Mechanics of Exercise .

i.       Delivery   of   Certificates   Upon   Exercise.   Certificates   for   shares   purchased

hereunder   shall   be   transmitted   by   the   transfer   agent   of   the   Company   to   the   Holder   by

crediting    the    account    of    the    Holder s    prime    broker    with    the    Depository    Trust

Company   through   its   Deposit   Withdrawal   Agent   Commission   ( DWAC )   system   if

the  Company  is  a  participant  in  such  system  and  either  (x)  there  is  an  effective

registration statement permitting the resale of the Warrant Shares by the Holder, or (y)

such   shares   may   be   sold   pursuant   to   Rule   144,   and   otherwise   by   physical   delivery   to

the   address   specified   by   the   Holder   in   the   Notice   of   Exercise,   within   3   Trading   Days

from   the   delivery   to   the   Company   of   the   Notice   of   Exercise   Form,   surrender   of   this

Warrant   (if   required)   and   payment   of   the   aggregate   Exercise   Price   as   set   forth   above

3

Warrant PRLX, T1, 2019-02-27



( Warrant    Share    Delivery    Date ).      This    Warrant    shall    be    deemed    to    have    been

exercised   on   the   date   the   Exercise   Price   is   received   by   the   Company.   The   Warrant

Shares  shall  be  deemed  to  have  been  issued,  and  Holder  or  any  other  person  so

designated   to   be   named   therein   shall   be   deemed   to   have   become   a   holder   of   record   of

such shares for all purposes, as of the date the Warrant has been exercised   by payment

to   the   Company   of   the   Exercise   Price   (or   by   cashless   exercise)   and   all   taxes   required

to   be   paid   by   the   Holder,   if   any,   pursuant   to   Section   2(e)(vi)   prior   to   the   issuance   of

such   shares,   have   been   paid.   If   the   Company   fails   for   any   reason   to   deliver   to   the

Holder   the   Warrant   Shares   or   certificates   evidencing   the   Warrant   Shares   subject   to   a

Notice   of   Exercise   by   the   Warrant   Share   Delivery   Date   the   Company   shall   pay   to   the

Holder,   in   cash,   as   liquidated   damages   and   not   as   a   penalty,   $1,000.00   per   Trading

Day   (increasing   to   $2,000.00   per   Trading   Day   on   the   fifth   Trading   Day   after   such

liquidated   damages   begin   to   accrue)   for   each   Trading   Day   after   such   Warrant   Share

Delivery Date until such shares or certificates are delivered.

ii.       Delivery of   New   Warrants   Upon   Exercise.    If   this   Warrant   shall   have   been

exercised   in   part,   the   Company shall,   at   the   request   of   a   Holder   and   upon   surrender   of

this    Warrant    certificate,    at    the    time    of    delivery    of    the    certificate    or    certificates

representing Warrant Shares, deliver to Holder a   new Warrant evidencing the rights of

Holder   to   purchase   the   unpurchased   Warrant   Shares   called   for   by this   Warrant,   which

new Warrant shall in all other respects be identical with this Warrant.

iii.       Rescission  Rights .    If  the  Company  fails  to  cause  its  transfer  agent  to

transmit   to   the   Holder   a   certificate   or   certificates   representing   the   Warrant   Shares   (or

otherwise   transmit   such   shares   via   DWAC   to   the   Holders   DTC   account)   pursuant   to

this   Section   2(e)   by   the   Warrant   Share   Delivery   Date,   then   the   Holder   will   have   the

right to rescind such exercise.

iv.       Compensation   for   Buy-In   on   Failure   to   Timely   Deliver   Certificates   Upon

Exercise.    In   addition   to   any   other   rights   available   to   the   Holder,   if   the   Company   fails

to    cause    its    transfer    agent    to    transmit    to    the    Holder    a    certificate    or    certificates

representing   the   Warrant   Shares   (or   otherwise   transmit   such   shares   via   DWAC   to   the

Holders    DTC    account)    pursuant    to    an    exercise    on    or    before    the    Warrant    Share

Delivery Date and if after such date the Holder is required by its broker to purchase (in

an   open   market   transaction   or   otherwise)   or   the   Holder s   brokerage   firm   otherwise

purchases,   shares   of   Common   Stock   to   deliver   in   satisfaction   of   a   sale   by   the   Holder

of   the   Warrant   Shares   which   the   Holder   anticipated   receiving   upon   such   exercise   (a

Buy-In ),   then   the   Company shall   (1)   pay in   cash   to   the   Holder   the   amount   by which

(x) the Holder s total purchase price (including brokerage   commissions, if any)   for the

shares   of   Common   Stock   so   purchased   exceeds   (y)   the   amount   obtained   by

multiplying   (A)   the   number   of   Warrant  Shares  that  the   Company   was  required  to

deliver   to   the   Holder   in   connection   with   the   exercise   at   issue   times   (B)   the   price   at

which   the   sell   order   giving   rise   to   such   purchase   obligation   was   executed,   and   (2)   at

the   option   of   the   Holder,   either   reinstate   the   portion   of   the   Warrant   and   equivalent

number   of   Warrant   Shares   for   which   such   exercise   was   not   honored   or   deliver   to   the

Holder   the   number   of   shares   of   Common   Stock   that   would   have   been   issued   had   the

Company   timely   complied   with   its   exercise   and   delivery   obligations   hereunder.   For

example,   if   the   Holder   purchases   Common   Stock   having   a   total   purchase   price   of

$11,000.00  to  cover  a  Buy-In  with  respect  to  an  attempted  exercise  of  shares  of

Common   Stock   with   an aggregate   sale   price   giving rise   to   such   purchase   obligation   of

4

Warrant PRLX, T1, 2019-02-27



$10,000.00,  under  clause  (1)  of  the  immediately   preceding  sentence  the  Company

shall   be   required   to   pay the   Holder   $1,000.00.   The   Holder   shall   provide   the   Company

written   notice   indicating   the   amounts   payable   to   the   Holder   in   respect   of   the   Buy-In

and,   upon   request   of   the   Company,   evidence   of   the   amount   of   such   loss.     Nothing

herein    shall    limit    a    Holder s    right    to    pursue    any    other    remedies    available    to    it

hereunder,  at  law  or  in  equity  including,  without  limitation,  a  decree  of  specific

performance   and/or   injunctive   relief   with   respect   to   the   Company s   failure   to   timely

deliver   the   Warrant   Shares   or   certificates   representing   shares   of   Common   Stock   upon

exercise of the Warrant as required pursuant to the terms hereof.

v.       No   Fractional   Shares   or   Scrip.   No   fractional   shares   or   scrip   representing

fractional   shares   shall   be   issued   upon   the   exercise   of   this   Warrant.    As   to   any   fraction

of   a   share   which   Holder   would   otherwise   be   entitled   to   purchase   upon   such   exercise,

the   Company shall   at   its   election,   either   pay a   cash   adjustment   in   respect   of   such   final

fraction   in   an   amount   equal   to   such   fraction   multiplied   by the   Exercise   Price   or   round

up to the next whole share.

vi.       Charges,   Taxes   and   Expenses.    Issuance   of   certificates   for   Warrant   Shares

shall  be   made   without   charge   to   the   Holder   for   any   issue   or   transfer   tax  or   other

incidental   expense   in   respect   of   the   issuance   of   such   certificate,   all   of   which   taxes   and

expenses   shall   be   paid   by   the   Company,   and   such   certificates   shall   be   issued   in   the

name   of   the   Holder   or   in   such   name   or   names   as   may   be   directed   by   the   Holder;

provided,   however,   that   in   the   event   certificates   for   Warrant   Shares   are   to   be   issued   in

a   name   other   than   the   name   of   the   Holder,   this   Warrant   when   surrendered   for   exercise

shall   be   accompanied   by   the   Assignment   Form   attached   hereto   duly   executed   by   the

Holder;   and   the   Company   may   require,   as   a   condition   thereto,   the   payment   of   a   sum

sufficient to reimburse it for any transfer tax incidental thereto.

Section 3.

Certain Adjustments .

a)

Stock    Dividends    and    Splits.    If    the    Company,    at    any  time    while    this    Warrant    is

outstanding:   (A)   pays   a   stock   dividend   or   otherwise   make   a   distribution   or   distributions   on   shares   of

its   Common   Stock   or   any   other   equity   or   equity   equivalent   securities   payable   in   shares   of   Common

Stock   (which,   for   avoidance   of   doubt,   shall   not   include   any   shares   of   Common   Stock   issued   by   the

Company upon   exercise   of   this   Warrant),   (B)   subdivides   outstanding shares   of   Common   Stock   into a

larger number of shares,   (C) combines (including by way of reverse stock split) outstanding shares of

Common   Stock   into   a   smaller   number   of   shares,   or   (D)   issues   by   reclassification   of   shares   of   the

Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall

be   multiplied   by   a   fraction   of   which   the   numerator   shall   be   the   number   of   shares   of   Common   Stock

outstanding   immediately   before   such   event   and   of   which   the   denominator   shall   be   the   number   of

shares of Common Stock outstanding immediately after such event and the number of shares issuable

upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price

of   this   Warrant   shall   remain   unchanged.   Any   adjustment   made   pursuant   to   this   Section   3(a)   shall

become   effective   immediately   after   the   record   date   for   the   determination   of   stockholders   entitled   to

receive   such   dividend   or   distribution   and   shall   become   effective   immediately   after   the   effective   date

in the case of a subdivision, combination or re-classification.

b)

Subsequent   Equity   Sales.   Except   for   Dilutive   Issuances   (as   defined   below)   issued   to

Company   employees,   and   members   of   the   Company s   board   of   directors   if   the   Company   or   any

Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell or grant any

option   to   purchase,   or sell   or   grant   any right   to   reprice,   or   otherwise   dispose   of   or   issue   (or   announce

5

Warrant PRLX, T1, 2019-02-27



any offer,   sale,   grant   or   any option   to   purchase   or   other   disposition)   any Common   Stock   or securities

entitling any Person   to   acquire   shares   of   Common   Stock   (upon   conversion,   exercise   or   otherwise),   at

an   effective   price   per   share   less   than   the   then   Exercise   Price   (such   lower   price,   the   Base   Share

Price   and   such   issuances   collectively,   a   Dilutive   Issuance )   (if   the   holder   of   the   Common   Stock   or

Common   Stock   Equivalents   so   issued   shall   at  any   time,   whether   by   operation   of   purchase   price

adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to

warrants, options or rights per share   which   are   issued in connection with such issuance,   be   entitled   to

receive   shares   of   Common   Stock   at   an   effective   price   per   share   which   is   less   than   the   Exercise   Price,

such   issuance   shall   be   deemed   to   have   occurred   for   less   than   the   Exercise   Price   on   such   date   of   the

Dilutive   Issuance), then the Exercise Price shall be reduced and only reduced to equal the Base Share

Price,    and    the    number    of    Warrant    Shares    issuable    hereunder    shall    be    increased    such    that    the

aggregate   Exercise   Price   payable   hereunder,   after   taking   into   account   the   decrease   in   the   Exercise

Price,   shall   be   equal   to   the   aggregate   Exercise   Price   prior   to   such   adjustment.    Such   adjustment   shall

be   made   whenever   such   Common   Stock   or   Common   Stock   Equivalents   are   issued.   The   Company

shall  notify   the  Holder  in  writing,  no  later  than  the  Trading   Day   following   the  issuance  of  any

Common   Stock   or   Common   Stock   Equivalents   subject   to   this   Section   3(b),   indicating   therein   the

applicable  issuance  price,  or  applicable  reset  price,  exchange  price,  conversion  price  and  other

pricing   terms   (such   notice   the   Dilutive   Issuance   Notice ).    For   purposes   of   clarification,   whether   or

not  the  Company  provides  a    Dilutive    Issuance    Notice  pursuant  to  this  Section  3(b),    upon  the

occurrence   of   any Dilutive   Issuance,   after   the   date   of   such   Dilutive   Issuance   the   Holder   is   entitled   to

receive   a   number   of   Warrant   Shares   based   upon   the   Base   Share   Price   regardless   of   whether   the

Holder accurately refers to the Base Share Price in the Notice of Exercise.

c)

Subsequent  Rights  Offerings.    If  the  Company,  at  any   time  while  the  Warrant  is

outstanding,  shall  issue  rights,  options  or  warrants  to  all  holders  of  Common  Stock  (and  not  to

Holders) entitling them to subscribe for or purchase shares of Common Stock at a price per share less

than   the   closing price at   the   record   date   mentioned   below,   then   the   Exercise   Price   shall   be   multiplied

by  a  fraction,  of  which  the  denominator  shall  be  the  number  of  shares  of  the  Common  Stock

outstanding on   the   date   of   issuance   of   such   rights   or   warrants   plus   the   number   of   additional   shares   of

Common Stock offered for subscription or purchase, and of which the numerator shall be the number

of shares of the Common Stock outstanding on the date of issuance of such rights or warrants plus the

number   of   shares   which   the   aggregate   offering   price   of   the   total   number   of   shares   issued   (assuming

receipt   by   the   Company   in   full   of   all   consideration   payable   upon   exercise   of   such   rights,   options   or

warrants) would purchase at such closing price.  Such adjustment shall be made whenever such rights

or    warrants    are    issued,    and    shall    become    effective    immediately    after    the    record    date    for    the

determination of stockholders entitled to receive such rights, options or warrants.

d)

Pro Rata Distributions .  If the Company, at any time while this Warrant is outstanding,

shall   distribute   to   all   holders   of   Common   Stock   (and   not   to   Holders   of   the   Warrants)   evidences   of   its

indebtedness   or   assets   (including   cash   and   cash   dividends)   or   rights   or   warrants   to   subscribe   for   or

purchase   any security other   than   the   Common   Stock   (which   shall   be   subject   to   Section   3(b)),   then   in

each  such  case  the  Exercise  Price  shall  be  adjusted  by  multiplying  the  Exercise  Price  in  effect

immediately   prior   to   the   record   date   fixed   for   determination   of   stockholders   entitled   to   receive   such

distribution   by   a   fraction   of   which   the   denominator   shall   be   the   closing   price   determined   as   of   the

record   date   mentioned   above,   and   of   which   the   numerator   shall   be   such   closing   price   on   such   record

date   less   the   then   per   share   fair   market   value   at   such   record   date   of   the   portion   of   such   assets   or

evidence   of   indebtedness   so   distributed   applicable   to   one   outstanding   share   of   the   Common   Stock   as

determined   by the   Board   of   Directors   in   good   faith.    In   either   case   the   adjustments   shall   be   described

in  a  statement  provided  to  the  Holder  of  the  portion  of  assets  or  evidences  of  indebtedness  so

distributed   or   such   subscription   rights   applicable   to   one   share   of   Common   Stock.   Such   adjustment

6

Warrant PRLX, T1, 2019-02-27



shall   be   made   whenever   any   such   distribution   is   made   and   shall   become   effective   immediately   after

the record date mentioned above.

e)

Fundamental   Transaction.   If,   at   any   time   while   this   Warrant   is   outstanding,   (A)   the

Company   effects   any   merger   or   consolidation   of   the   Company   with   or   into   another   Person,   (B)   the

Company  effects  any  sale  of  all  or  substantially  all  of  its  assets  in  one  or  a  series  of  related

transactions,   (C)   any   tender   offer   or   exchange   offer   (whether   by   the   Company   or   another   Person)   is

completed   pursuant   to   which   holders   of   Common   Stock   are   permitted   to   tender   or   exchange   their

shares   for   other   securities,   cash   or   property,   or   (D)   the   Company   effects   any   reclassification   of   the

Common    Stock    or    any    compulsory    share    exchange    pursuant    to    which    the    Common    Stock    is

effectively   converted   into   or   exchanged   for   other   securities,   cash   or   property   (each   Fundamental

Transaction ),   then,   upon   any   subsequent   exercise   of   this   Warrant,   the   Holder   shall   have   the   right   to

receive,   for   each   Warrant   Share   that   would   have   been   issuable   upon   such   exercise   immediately prior

to   the   occurrence   of   such   Fundamental   Transaction,   the   number   of   shares   of   Common   Stock   of   the

successor   or   acquiring   corporation   or   of   the   Company,   if   it   is   the   surviving   corporation,   and   any

additional    consideration    (the    Alternate    Consideration )    receivable    as    a    result    of    such    merger,

consolidation   or   disposition   of   assets   by   a   holder   of   the   number   of   shares   of   Common   Stock   for

which this Warrant is exercisable immediately prior to such event. For purposes of any such exercise,

the   determination   of   the   Exercise   Price   shall   be   appropriately   adjusted   to   apply   to   such   Alternate

Consideration   based   on   the   amount   of   Alternate   Consideration   issuable   in   respect   of   one   share   of

Common   Stock   in   such   Fundamental   Transaction,   and   the   Company   shall   apportion   the   Exercise

Price   among   the   Alternate   Consideration   in   a   reasonable   manner   reflecting   the   relative   value   of   any

different   components   of   the   Alternate   Consideration.     If   holders   of   Common   Stock   are   given   any

choice   as   to   the   securities,   cash   or   property   to   be   received   in   a   Fundamental   Transaction,   then   the

Holder shall be   given the   same choice   as to the   Alternate Consideration it receives   upon any exercise

of   this   Warrant   following   such   Fundamental   Transaction.   To   the   extent   necessary   to   effectuate   the

foregoing    provisions,    any    successor    to    the    Company    or    surviving    entity    in    such    Fundamental

Transaction   shall   issue   to   the   Holder   a   new   warrant   consistent   with   the   foregoing   provisions   and

evidencing the Holder s right to exercise such warrant into Alternate Consideration. The terms of any

agreement pursuant to which a   Fundamental Transaction is effected   shall include terms requiring any

such successor or surviving entity to comply with the provisions of this Section 3(e) and insuring that

this  Warrant  (or  any   such  replacement  security)  will  be  similarly   adjusted  upon  any   subsequent

transaction analogous to a Fundamental Transaction. Notwithstanding anything to the contrary, in the

event   of   a   Fundamental   Transaction   that   is   (1)   an   all   cash   transaction,   (2)   a   Rule   13e-3   transaction

as    defined    in    Rule    13e-3    under    the    Securities    Exchange    Act    of    1934,    as    amended,    or    (3)    a

Fundamental   Transaction   involving   a   person   or   entity   not   traded   on   a   national   securities   exchange,

the   Nasdaq   Global   Select   Market,   the   Nasdaq   Global   Market,   or   the   Nasdaq   Capital   Market,   the

Company    or    any    successor    entity    shall    pay    at    the    Holder s    option,    exercisable    at    any    time

concurrently   with   or   within   30   days   after   the   consummation   of   the   Fundamental   Transaction,   an

amount of cash equal to the value of this Warrant as determined in accordance with the Black Scholes

Option Pricing Model obtained from the OV function on Bloomberg L.P. using (i) a price per share

of   Common   Stock   equal   to   the   closing   price   of   the   Common   Stock   for   the   Trading   Day immediately

preceding   the   date   of   consummation   of   the   applicable     Fundamental  Transaction,   (ii)  a   risk-free

interest   rate   corresponding   to   the   U.S.   Treasury   rate   for   a   period   equal   to   the   remaining   term   of   this

Warrant  as  of   the   date   of   consummation   of   the   applicable   Fundamental  Transaction   and  (iii)   an

expected   volatility   equal   to   the   100   day   volatility   obtained   from   the   HVT   function   on   Bloomberg

L.P.  determined  as  of  the  Trading  Day  immediately  following  the  public  announcement  of  the

applicable Fundamental Transaction.

7

Warrant PRLX, T1, 2019-02-27



f)

Calculations .   All   calculations   under   this   Section   3   shall   be   made   to   the   nearest   two

decimal   places   or   the   nearest   1/100th   of   a   share,   as   the   case   may   be.   For   purposes   of   this   Section   3,

the   number   of   shares   of   Common   Stock   deemed   to   be   issued   and   outstanding as   of   a   given   date   shall

be   the   sum   of   the   number   of   shares   of   Common   Stock   (excluding   treasury   shares,   if   any)   issued   and

outstanding.

g)

Notice to Holder .

i.       Adjustment  to  Exercise  Price .  Whenever  the  Exercise  Price  is  adjusted

pursuant   to   any   provision   of   this   Section   3,   the   Company   shall   promptly   mail   to   the

Holder   a   notice   setting forth   the   Exercise   Price   after   such   adjustment   and   setting forth

a brief statement of the facts requiring such adjustment.

ii.       Notice   to   Allow   Exercise   by   Holder .   If   (A)   the   Company   shall   declare   a

dividend   (or   any   other   distribution   in   whatever   form)   on   the   Common   Stock;   (B)   the

Company shall   declare   a   special   nonrecurring cash   dividend   on   or   a   redemption   of   the

Common   Stock;   (C)   the   Company   shall   authorize   the   granting   to   all   holders   of   the

Common   Stock   rights   or   warrants   to   subscribe   for   or   purchase   any   shares   of   capital

stock  of  any  class  or  of  any  rights;  (D)  the  approval  of  any  stockholders  of  the

Company   shall   be   required   in   connection   with   any   reclassification   of   the   Common

Stock,   any   consolidation   or   merger   to   which   the   Company   is   a   party,  any   sale   or

transfer   of   all   or   substantially   all   of   the   assets   of   the   Company,   of   any   compulsory

share   exchange   whereby   the   Common   Stock   is   converted   into   other   securities,   cash   or

property;   (E)   the   Company   shall   authorize   the   voluntary   or   involuntary   dissolution,

liquidation  or  winding  up  of  the  affairs  of  the  Company;  then,  in  each  case,  the

Company   shall   cause   to   be   mailed   to   the   Holder   at   its   last   address   as   it   shall   appear

upon  the  Warrant  Register  of  the  Company,  at  least  7  business  days  prior  to  the

applicable record or effective date hereinafter specified, a notice stating (x) the date on

which    a    record    is    to    be    taken    for    the    purpose    of    such    dividend,    distribution,

redemption,   rights   or   warrants,   or   if   a   record   is   not   to   be   taken,   the   date   as   of   which

the    holders    of    the    Common    Stock    of    record    to    be    entitled    to    such    dividend,

distributions,   redemption,   rights   or   warrants   are   to   be   determined   or   (y)   the   date   on

which   such   reclassification,   consolidation,   merger,   sale,   transfer   or   share   exchange   is

expected   to   become   effective   or   close,   and   the   date   as   of   which   it   is   expected   that

holders   of   the   Common   Stock   of   record   shall   be   entitled   to   exchange   their   shares   of

the    Common    Stock    for    securities,    cash    or    other    property    deliverable    upon    such

reclassification,   consolidation,   merger,   sale,   transfer   or   share   exchange;   provided   that

the   failure   to   mail   such   notice   or   any defect   therein   or   in   the   mailing   thereof   shall   not

affect   the   validity of   the   corporate   action   required   to   be   specified   in   such   notice.    The

Holder   is   entitled   to   exercise   this   Warrant   during   the   period   commencing   on   the   date

of such notice to the effective date of the event triggering such notice.

Section 4.

Transfer of Warrant.

a)

Transferability .     Subject   to   compliance   with   any   applicable   securities   laws   and   the

conditions  set  forth   in  Section   4(d)   hereof  and  to   the   provisions  of   Section   4.1   of   the   Purchase

Agreement,  this  Warrant  and  all  rights  hereunder  (including,  without  limitation,  any   registration

rights)   are   transferable,   in   whole   or   in   part,   upon   surrender   of   this   Warrant   at   the   principal   office   of

the Company or its designated agent, together with a written assignment of   this Warrant substantially

in   the   form   attached   hereto   duly   executed   by   the   Holder   or   its   agent   or   attorney   and   funds   sufficient

to   pay   any   transfer   taxes   payable   upon   the   making   of   such   transfer.     Upon   such   surrender   and,   if

8

Warrant PRLX, T1, 2019-02-27



required,   such   payment,   the   Company   shall   execute   and   deliver   a   new   Warrant   or   Warrants   in   the

name  of  the  assignee  or  assignees  and  in  the  denomination  or  denominations  specified  in  such

instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this

Warrant  not  so   assigned,   and   this  Warrant  shall  promptly   be   cancelled.    A   Warrant,  if   properly

assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new

Warrant issued.

b)

New   Warrants.   This   Warrant   may   be   divided   or   combined   with   other   Warrants   upon

presentation   hereof   at   the   aforesaid   office   of   the   Company,   together   with   a   written   notice   specifying

the   names   and   denominations   in   which   new   Warrants   are   to   be   issued,   signed   by   the   Holder   or   its

agent or attorney.    Subject to compliance with Section 4(a), as to any transfer which may be involved

in   such   division   or   combination,   the   Company   shall   execute   and   deliver   a   new   Warrant   or   Warrants

in   exchange   for   the   Warrant   or   Warrants   to   be   divided   or   combined   in   accordance   with   such   notice.

All   Warrants   issued   on   transfers   or   exchanges   shall   be   dated   the   original   Issue   Date   and   shall   be

identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c)

Warrant    Register.    The    Company  shall    register    this    Warrant,    upon    records    to    be

maintained   by   the   Company   for   that   purpose   (the   Warrant   Register ),   in   the   name   of   the   record

Holder   hereof   from   time   to   time.   The   Company   may   deem   and   treat   the   registered   Holder   of   this

Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the

Holder, and for all other purposes, absent actual notice to the contrary.

d)

Transfer   Restrictions.   If,   at   the   time   of   the   surrender   of   this   Warrant   in   connection

with   any   transfer   of   this   Warrant,   the   transfer   of   this   Warrant   shall   not   be   registered   pursuant   to   an

effective   registration   statement   under   the   Securities   Act   and   under   applicable   state   securities   or   blue

sky   laws   or   eligible   for   resale   under   Rule   144,   the   Company may   require,   as   a   condition   of   allowing

such   transfer,   that   the   Holder   or   transferee   of   this   Warrant,   as   the   case   may   be,   comply   with   the

provisions of Section 5.7 of the Purchase Agreement.

Section 5.

Miscellaneous.

a)

No   Rights   as   Shareholder   Until   Exercise .    This   Warrant   does   not   entitle   the   Holder   to

any   voting   rights   or   other   rights   as   a   shareholder   of   the   Company   prior   to   the   exercise   hereof   as   set

forth in Section 2(e)(i).

b)

Loss,   Theft,   Destruction   or   Mutilation   of   Warrant.   The   Company   covenants   that   upon

receipt   by   the   Company   of   evidence   reasonably   satisfactory   to   it   of   the   loss,   theft,   destruction   or

mutilation   of   this   Warrant   or   any stock   certificate   relating   to   the   Warrant   Shares,   and   in   case   of   loss,

theft   or   destruction,   of   indemnity   or   security   reasonably   satisfactory   to   it   (which,   in   the   case   of   the

Warrant,   shall   not   include   the   posting   of   any   bond),   and   upon   surrender   and   cancellation   of   such

Warrant or stock certificate, if mutilated, the Company will make   and deliver a new Warrant or stock

certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c)

Saturdays,   Sundays,   Holidays,   etc .   If   the   last   or   appointed   day   for   the   taking   of   any

action or the expiration of any right required or   granted herein shall not be a Business Day, then such

action may be taken or such right may be exercised on the next succeeding Business Day.

d)

Authorized Shares.

The   Company   covenants   that   during   the   from   the   Issue   Date   herein   it   will

reserve   from   its   authorized   and   unissued   Common   Stock,   the   number   of   shares   of   Common

9

Warrant PRLX, T1, 2019-02-27



Stock   equal   to   700%   of   the   total   shares   of   Common   Stock   issuable   upon   the   full   exercise   of

this   Warrant   (without   regard   to   the   beneficial   ownership   limitations   contained   herein).   The

Company   further   covenants   that   its   issuance   of   this   Warrant   shall   constitute   full   authority   to

its   officers   who   are   charged   with   the   duty of   executing   stock   certificates   to   execute   and   issue

the   necessary   certificates   for   the   Warrant   Shares   upon   the   exercise   of   the   purchase   rights

under this Warrant.  The Company will take all such reasonable action as may be necessary to

assure   that   such   Warrant   Shares   may   be   issued   as   provided   herein   without   violation   of   any

applicable   law   or   regulation,   or   of   any   requirements   of   the   trading   market   upon   which   the

Common   Stock   may   be   listed.    The   Company   covenants   that   all   Warrant   Shares   which   may

be   issued   upon   the   exercise   of   the   purchase   rights   represented   by   this   Warrant   will,   upon

exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued,

fully  paid    and    nonassessable    and    free    from    all    taxes,    liens    and    charges    created    by  the

Company   in   respect   of   the   issue   thereof   (other   than   taxes   in   respect   of   any   transfer   occurring

contemporaneously with such issue).

Except   and   to   the   extent   as   waived   or   consented   to   by   the   Holder,   the   Company   shall

not   by   any   action,   including,   without   limitation,   amending   its   certificate   of   incorporation   or

through   any reorganization, transfer of   assets,   consolidation, merger, dissolution, issue or sale

of    securities    or    any    other    voluntary    action,    avoid    or    seek    to    avoid    the    observance    or

performance of any of the terms of this Warrant, but will at all times in good faith assist in the

carrying   out   of   all   such   terms   and   in   the   taking   of   all   such   actions   as   may   be   necessary   or

appropriate   to   protect   the   rights   of   Holder   as   set   forth   in   this   Warrant   against   impairment.

Without   limiting   the   generality   of   the   foregoing,   the   Company   will   (a)   not   increase   the   par

value    of    any    Warrant    Shares    above    the    amount    payable    therefor    upon    such    exercise

immediately   prior   to   such   increase   in   par   value,   (b)   take   all   such   action   as   may   be   necessary

or  appropriate  in  order  that  the  Company  may  validly  and  legally  issue  fully  paid  and

nonassessable   Warrant   Shares   upon   the   exercise   of   this   Warrant,   and   (c)   use   commercially

reasonable   efforts   to   obtain   all   such   authorizations,   exemptions   or   consents   from   any   public

regulatory   body   having   jurisdiction   thereof   as   may   be   necessary   to   enable   the   Company   to

perform its obligations under this Warrant.

e)

Jurisdiction .  All    questions    concerning  the    construction,    validity,    enforcement    and

interpretation   of   this   Warrant   shall   be   determined   in   accordance   with   the   provisions   of   the   Purchase

Agreement.

f)

Restrictions .     The   Holder   acknowledges   that   the   Warrant   Shares   acquired   upon   the

exercise   of   this   Warrant,   if   not   registered,   will   have   restrictions   upon   resale   imposed   by   state   and

federal securities laws.

g)

Nonwaiver and Expenses.  No course of dealing or any delay or failure to exercise any

right   hereunder   on   the   part   of   Holder   shall   operate   as   a   waiver   of   such   right   or   otherwise   prejudice

Holder s   rights,   powers   or   remedies,   notwithstanding   the   fact   that   all   rights   hereunder   terminate   on

the   Expiration   Date.    If   the   Company   willfully   and   knowingly   fails   to   comply   with   any   provision   of

this   Warrant,   which   results   in   any material   damages   to   the   Holder,   the   Company   shall   pay   to   Holder

such   amounts   as   shall   be   sufficient   to   cover   any   costs   and   expenses   including,   but   not   limited   to,

reasonable   attorneys   fees,   including   those   of   appellate   proceedings,   incurred   by Holder   in   collecting

any   amounts   due   pursuant   hereto   or   in   otherwise   enforcing   any   of   its   rights,   powers   or   remedies

hereunder.

10

Warrant PRLX, T1, 2019-02-27



h)

Notices.    Any   notice,   request   or   other   document   required   or   permitted   to   be   given   or

delivered   to   the   Holder   by   the   Company   shall   be   delivered   in   accordance   with   the   notice   provisions

of the Purchase Agreement.

i)

Limitation   of   Liability .    No   provision   hereof,   in   the   absence   of   any   affirmative   action

by   Holder   to   exercise   this   Warrant   to   purchase   Warrant   Shares,   and   no   enumeration   herein   of   the

rights   or   privileges   of   Holder,   shall   give   rise   to   any   liability   of   Holder   for   the   purchase   price   of   any

Common  Stock  or  as  a  stockholder  of  the  Company,  whether  such  liability  is  asserted  by  the

Company or by creditors of the Company.

j)

Remedies.    Holder,   in   addition   to   being   entitled   to   exercise   all   rights   granted   by   law,

including  recovery  of  damages,  will  be  entitled  to  specific  performance  of  its  rights  under  this

Warrant.    The   Company   agrees   that   monetary damages   would   not   be   adequate   compensation   for   any

loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive

and   not   to   assert   the   defense   in   any   action   for   specific   performance   that   a   remedy   at   law   would   be

adequate.

k)

Successors   and   Assigns.   Subject   to   applicable   securities   laws,   this   Warrant   and   the

rights  and  obligations  evidenced  hereby  shall  inure  to  the  benefit  of  and  be  binding  upon  the

successors   of   the   Company   and   the   successors   and   permitted   assigns   of   Holder.   The   provisions   of

this   Warrant   are   intended   to   be   for   the   benefit   of   all   Holders   from   time   to   time   of   this   Warrant   and

shall be enforceable by the Holder or holder of Warrant Shares.

l)

Amendment.     This   Warrant   may   be   modified   or   amended   or   the   provisions   hereof

waived with the written consent of the Company and the Holder.

m)

Severability .    Wherever possible, each provision of this Warrant shall be interpreted in

such   manner   as   to   be   effective   and   valid   under   applicable   law,   but   if   any   provision   of   this   Warrant

shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent

of  such  prohibition  or    invalidity,    without  invalidating  the    remainder  of  such  provisions  or  the

remaining provisions of this Warrant.

n)

Headings.     The   headings   used   in   this   Warrant   are   for   the   convenience   of   reference

only and shall not, for any purpose, be deemed a part of this Warrant.

o)

Signatures.    Any   signature   transmitted   by   facsimile,   e-mail,   or   other   electronic   means

shall be deemed to be an original signature.

IN   WITNESS   WHEREOF,   the   Company   has   caused   this   Warrant   to   be   executed   by   its   officer   thereunto

duly authorized as of the date first above indicated.

PARALLAX HEALTH SCIENCES, INC.

By:__________________________________________

Name:  Paul R. Arena

Title: CEO

11

Warrant PRLX, T1, 2019-02-27



NOTICE OF EXERCISE

TO: PARALLAX HEALTH SCIENCES, INC.

RE:      Warrant  originally  issued  on  or  about  February  27,  2019  to  EMA  Financial,  LLC  for  300,000

Warrant Shares.

(1)   The  undersigned  hereby  elects  to  purchase  _______________  Warrant  Shares  of  the

Company   pursuant   to   the   terms   of   the   attached   Warrant   (only   if   exercised   in   full),   and   tenders   herewith

payment   of   the   exercise   price   in   full,   together   with   all   applicable   transfer   taxes,   if   any.   Total   shares   of

common stock to be issued:

.

(2)   Payment shall take the form of (check applicable box):

[  ] in lawful money of the United States; or

[   ]   the   cancellation   of   such   number   of   Warrant   Shares   as   is   necessary,   in   accordance

with   the   formula   set   forth   in   subsection   2(c),   to   exercise   this   Warrant   with   respect   to

the maximum number of Warrant Shares purchasable pursuant to the cashless exercise

procedure set forth in subsection 2(c).

(3)   Please   issue   a   certificate   or   certificates   representing   said   Warrant   Shares   in   the   name   of

the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a

certificate to:

_______________________________

_______________________________

_______________________________

(4)      Accredited    Investor .     The    undersigned    is    an    accredited    investor    as    defined    in

Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Warrant Holder: ________________________________________________________________________

Signature of Authorized Signatory of Warrant Holder : _________________________________________________

Name of Authorized Signatory: ___________________________________________________________________

Title of Authorized Signatory: ____________________________________________________________________

Date: ________________________________________________________________________________________

12

Warrant PRLX, T1, 2019-02-27



ASSIGNMENT FORM

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all

rights evidenced thereby are hereby assigned to

_______________________________________________ whose address is

_______________________________________________________________.

_______________________________________________________________

Dated:  ______________, _______

Holder s Signature:     _____________________________

Holder s Address:

_____________________________

_____________________________

Signature Guaranteed:  ___________________________________________

NOTE:    The   signature   to   this   Assignment   Form   must   correspond   with   the   name   as   it   appears   on   the   face   of

the   Warrant,   without   alteration   or   enlargement   or   any change   whatsoever,   and   must   be   guaranteed   by a   bank

or   trust   company.   Officers   of   corporations   and   those   acting   in   a   fiduciary   or   other   representative   capacity

should file proper evidence of authority to assign the foregoing Warrant.

13

Warrant PRLX, T1, 2019-02-27